

Accepted Manuscript

Title: Noninvasive brain stimulation to suppress craving in substance use disorders: review of human evidence and methodological considerations for future work

Author: Antoine Hone-Blanchet Domenic A Ciraulo Alvaro Pascual-Leone Shirley Fecteau



PII: S0149-7634(15)00253-5
DOI: <http://dx.doi.org/doi:10.1016/j.neubiorev.2015.10.001>
Reference: NBR 2280

To appear in:

Received date: 25-6-2014
Revised date: 10-9-2015
Accepted date: 1-10-2015

Please cite this article as: Hone-Blanchet, A., Ciraulo, D.A., Pascual-Leone, A., Fecteau, S., Noninvasive brain stimulation to suppress craving in substance use disorders: review of human evidence and methodological considerations for future work, *Neuroscience and Biobehavioral Reviews* (2015), <http://dx.doi.org/10.1016/j.neubiorev.2015.10.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Highlights**

- 2 1. We have reviewed studies using rTMS and tES to reduce craving in SUDs
3 2. Both brain stimulation techniques can induce significant changes in craving
4 3. Craving reduction did not reach clinical significance in all studies
5 4. Methodological discrepancies may explain the different conclusions
6 5. Parameters need to be addressed in future works to promote therapeutic potential

7

8 **Title:** Noninvasive brain stimulation to suppress craving in substance use disorders: review of human
9 evidence and methodological considerations for future work

10 **Authors:** Antoine Hone-Blanchet¹, Domenic A Ciraulo³, Alvaro Pascual-Leone², Shirley Fecteau^{1,2}

11

12 **Affiliations:**

- 13 1) Laboratory of Canada Research Chair in Cognitive Neuroscience, Centre Interdisciplinaire de
14 Recherche en Réadaptation et Intégration Sociale, Centre de Recherche l'Institut Universitaire
15 en Santé Mentale de Québec, Medical School, Laval University, Canada;
16 2) Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical
17 Center, Harvard Medical School, USA;
18 3) Massachusetts General Hospital, Harvard Medical School, USA.

19

20 **Funding:**

21 This work was supported by a scholarship from Centre Interdisciplinaire de Recherche en Réadaptation
22 et Intégration Sociale and Fonds de la Recherche du Québec, Santé to AHB, grants from the Sidney R.
23 Baer Jr. Foundation, the National Institutes of Health (R01HD069776, R01NS073601, R21
24 MH099196, R21 NS082870, R21 NS085491, R21 HD07616, UL1 RR025758), and Harvard Catalyst |
25 The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH 8KL2TR000168-
26 05) to APL, and grants from the National Science and Engineering Research Council and Canada
27 Research Chair to SF. The content is solely the responsibility of the authors and does not necessarily
28 represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health
29 care centers, the National Institutes of Health or the Sidney R. Baer Jr. Foundation.

30 **Corresponding author contact information:**

31 1050, avenue de la Médecine, Université Laval, Québec (Québec) Canada, G1V 0A6.
32 Shirley.fecteau@fmed.ulaval.ca

33

34

34 Abstract

35

36 Substance use disorders (SUDs) can be viewed as a pathology of neuroadaptation. The
37 pharmacological overstimulation of neural mechanisms of reward, motivated learning and memory
38 leads to drug-seeking behavior. A critical characteristic of SUDs is the appearance of craving, the
39 motivated desire and urge to use, which is a main focus of current pharmacological and behavioral
40 therapies. Recent proof-of-concept studies have tested the effects of non-invasive brain stimulation on
41 craving. Although its mechanisms of action are not fully understood, this approach shows interesting
42 potential in tuning down craving and possibly consumption of diverse substances. This article reviews
43 available results on the use of repetitive transcranial magnetic stimulation (rTMS) and transcranial
44 electrical stimulation (tES) in SUDs, specifically tobacco, alcohol and psychostimulant use disorders.
45 We discuss several important factors that need to be addressed in future works to improve clinical
46 assessment and effects of non-invasive brain stimulation in SUDs. Factors discussed include brain
47 stimulation devices and parameters, study designs, brain states and subjects' characteristics.

48

49

50 Introduction

51

52 Substance use disorders (SUDs) have been extensively studied in animal and human models in the last
53 decades and growing lines of investigation suggest that SUDs are the end product of a neuroadaptive
54 pathology. The pharmacological usurpation of neural mechanisms of reward, motivated learning and
55 memory can lead to drug-seeking behavior and craving (Feil and Zangen, 2010; Hyman, 2007; Kalivas
56 and O'Brien, 2007; Koob and Volkow, 2009). Despite extensive research, current treatments including
57 pharmacological and behavioral therapies have limited efficacy in reducing craving and promoting
58 complete abstinence of substance use (Anton et al., 2006) and SUDs still have a costly impact on
59 healthcare worldwide. There is thus a need to explore novel approaches to treat SUDs.

60

61 Non-invasive brain stimulation (NIBS) techniques, namely repetitive transcranial magnetic stimulation
62 (rTMS) and transcranial electrical stimulation (tES) are being investigated as new approaches to reduce
63 craving and treat SUDs. rTMS uses the principle of electromagnetic induction to modulate cortical
64 excitability. Repeated sessions of rTMS can induce long-lasting and durable neurophysiological
65 changes in targeted brain structures and modulate behaviours associated with cortical functioning (e.g.,
66 (Wagner et al., 2004). The neurophysiological effects of rTMS are dependent on several parameters,
67 including the frequency of stimulation, the number of pulses delivered per train of stimulation, the
68 intertrain interval, the length of the stimulation period and the targeted cortical area. tES uses direct or
69 alternative electrical current, applied to the scalp traveling from a positive (cathode) to a negative
70 (anode) electrode. Under the anode, cortical neurons are thought to be facilitated whereas under the
71 cathode, cortical neurons are believed to be suppressed (Nitsche et al., 2003). rTMS is approved by the
72 FDA for the treatment of refractory major depression (George et al., 1997; 1995; O'Reardon et al.,
73 2007; Pascual-Leone et al., 1996). rTMS and tES have also been studied with success in the reduction
74 of auditory hallucinations and positive symptoms in schizophrenia, neuropathic pain and anxiety
75 disorders (Kuo et al., 2013; Wassermann and Lisanby, 2001).

76

77 Both, rTMS and tES have shown some promise in the treatment of SUDs. Although preliminary,
78 emerging results provide encouraging data (Feil and Zangen, 2010; Jansen et al., 2013; Wing et al.,
79 2012). The goal of this review is to present the current state of understanding of craving and SUDs and
80 summarize the findings on the use of NIBS in SUDs. We focus here on craving because it is now a
81 DSM 5 criterion for SUD. Craving is also considered a predictive factor of relapse following a quit

82 attempt because of abnormal cue-reactivity in SUD patients (Baker et al., 2012; Goudriaan et al., 2010;
83 Paulus et al., 2005; Hone-Blanchet et al., 2014) but this concept is still disputed (Perkins, 2012). For
84 instance, in tobacco use disorder (TUD), it is suggested that therapies for smoking cessation should
85 tune down cue-induced craving (Ferguson and Shiffman, 2009). Therefore, new alternative therapeutic
86 modalities, aiming at controlling craving and promoting long-term abstinence, are needed.

87
88 Craving is a complex concept, encompassing neurobiological and psychosocial variables. It is defined
89 as the desire for the previously experienced effects of a psychoactive drug, motivated by internal and
90 external cues (Hyman, 2007). Repeated and intense firing of dopamine neurons provides the
91 pleasurable sensations associated with substance intake. Although psychoactive substances act through
92 an extremely wide range of active compounds with specific neuropharmacological mechanisms of
93 action (Stahl, 2005), an essential pharmacological endpoint remains dopamine release through the
94 mesocorticolimbic pathways. Intoxication is thus associated with diverse effects, dependent on the
95 substance's properties, and repetition of intake and binges allow the replication of this dopamine-firing
96 pattern. More importantly, this repeated pattern associates incentive salience to external stimuli and
97 promotes drug-related goal-directed actions and motivational behavior. Dopamine signaling from the
98 ventral tegmental area to the ventral striatum (e.g., nucleus accumbens) and prefrontal cortices initiates
99 drug-seeking behaviour, but recruitment of the central nucleus of the amygdala, ventral pallidum and
100 dorsal striatum eventually reinforces compulsive drug-seeking. During withdrawal, the shift from
101 constant drug-related reward to abstinence is primarily characterized with reduced DA neurons firing.
102 This recruits the extended amygdala (including the central nucleus of the amygdala and the shell part of
103 the nucleus accumbens) that mediates limbic and motor influxes, resulting in the appearance of a broad
104 range of withdrawal symptoms (Koob & Volkow, 2009). Moreover, this metabolic stress results in
105 elevated corticotropin-releasing factor in the central amygdala, thus facilitating the impact of drug cues
106 and stressors on the possibility of relapse. Stress is a key part in the maintenance of SUDs, as it is
107 thought to facilitate the reinstatement of drug-seeking behavior through the sustained action of
108 corticotropin-releasing factor in the amygdala. Corticostriatal glutamatergic pathways from the
109 prefrontal cortices to the nucleus accumbens mediate drug-induced reinstatement. Furthermore, the
110 recruitment of the basolateral nucleus of the amygdala and hippocampus is also important in the
111 attribution and valuation of drug-cues, thus being extremely important in drug-related cue-
112 reinstatement (Koob & Volkow, 2009).

113
114 It has been shown in multiple works that craving can be induced by environmental cues alone,
115 independently from the state of abstinence (Franklin et al., 2007). Successful abstinence is consistently
116 associated with the capacity to resist craving. Therefore, reduction of craving and/or ability to resist
117 craving, may thus represent critical objectives and major therapeutical outcomes across SUDs (see
118 Figure 1). A balance between reflective (i.e decision-making, executive) and reflexive (i.e reward-
119 biased, impulsive) systems is thought to regulate drug-related behavior, and more generally, reward-
120 associated behavior and response to craving (Bechara et al., 2005). The reflective system exerts top-
121 down control on the impulsive system, thus regulating emotions and affective states. However,
122 decision-making is a complex process that requires integration of information and can thus be
123 influenced by the reflexive system. Chronic drug consumption would facilitate a hyperactivity and
124 hypersensitivity of the reflexive system, overcoming the reflective system. This neurocognitive model
125 is strongly based on neuroanatomical organization of the reward system, with a limbic drive circuit
126 comprising projections from the medial prefrontal cortex to the nucleus accumbens (the reflexive
127 system), and an executive control circuit comprising projections from the DLPFC to the dorsal part of
128 the striatum (the reflective system) (Hanlon et al., 2015).

130 There are currently various experimental measurements of craving. Craving can be induced by transient
131 abstinence and by presentation of salient sensorial cues. Measure of craving presently relies on the use
132 of standardized questionnaires. Although physiological measurements (i.e.: skin conductance, heartbeat
133 rate, serum cortisol) are also used in some studies, they are not reliable and objective correlates of
134 craving, hence making craving an important but difficult outcome measure.

135

136 Please insert Figure 1 about here

137

138 The following sections review results focusing on the changes relative to craving and substance use
139 induced by NIBS in the context of TUD, alcohol use disorder (AUD) and psychostimulant use disorder.
140 Of note, studies detailed below do not use the same definition of TUD, AUD, and psychostimulant use
141 disorders and many were completed before the DSM 5 edition. We thus use the authors' own
142 terminology in the description of subjects and substance use. Finally, we propose possible mechanisms
143 underlying the beneficial effects of NIBS in reducing craving and critical methodological factors to
144 consider for future works.

145

146

147 **Noninvasive brain stimulation in tobacco use disorder**

148

149 Cigarette smoking is still the leading cause of premature death and illness in many countries. Currently
150 available pharmacotherapeutical alternatives, such as bupropion and varenicline, decrease nicotine
151 craving by respectively stimulating the dopamine and GABA pathways but reported side effects are
152 important. Nicotine replacement therapy (nicotine gums, patches and inhalators) replaces nicotine
153 inhaled during cigarette smoking. Although these methods may help transiently decrease craving for
154 cigarettes, smoking cessation rates appear to not exceed 35% despite use of these treatments (Benowitz,
155 2009).

156

157 *Neural substrates of tobacco use disorders*

158 Nicotine inhaled from cigarette smoke is carried from the lungs to the brain where it selectively binds
159 to nicotinic cholinergic receptors (nAChRs). Direct stimulation of these receptors activates the
160 liberation of dopamine in the mesocorticolimbic pathways, among other neurotransmitters. Acute and
161 repeated chronic effects of nicotine result in the activation of the prefrontal cortex, visual areas and
162 thalamus. Nicotine intake increases dopamine concentration in the ventral tegmental area (VTA),
163 nucleus accumbens (NA) and striatum, which is thought to provide the pleasurable and arousing effects
164 of cigarette smoking. The stimulation of dopamine pathways also allows the liberation of GABA and
165 glutamate, neurotransmitters that respectively have inhibiting and facilitating effects on dopamine
166 transmission. Chronic use of nicotine tones down the inhibitory action of GABA release but maintains
167 the release of glutamate, which facilitates the release of dopamine and enhances the reinforcing effects
168 of nicotine. Other hypotheses of the development of nicotine SUD point at the reduction of the activity
169 of monoamine oxidase A and B (MAO-A and MAO-B), both enzymes involved in the catalysis of
170 catecholamines (Schwartz and Benowitz, 2010). Importantly, nicotine also stimulates the release of
171 acetylcholine, serotonin, norepinephrine and endorphins, triggering a global neurophysiological
172 response which may induce alterations in neuronal activity and excitability (Markou, 2008). Single and
173 paired-pulse TMS paradigms as applied for example by Lang et al. (2007) have demonstrated that
174 chronic nicotine intake may increase cortical inhibition, with smaller amplitude of motor evoked
175 potentials and increased afferent inhibition in smokers compared to healthy controls.

176

177 There is also rich neuroimaging literature showing the activation of a complex network which includes
178 the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OFC), and the striatum during

179 craving-inducing exposure to smoking cues (Brody, 2006; Goldstein and Volkow, 2002; McBride et
180 al., 2006; Wilson et al., 2004). Importantly, the DLPFC is a cortical relay in the mesocortical dopamine
181 pathway, stimulated during craving and substance use and thus a key brain structure in the development
182 and maintenance of TUD. The DLPFC has thus been the main brain region targeted with NIBS.

183
184 ***Repetitive transcranial magnetic stimulation in tobacco use disorders***

185 Studies have investigated the effect of single or repeated sessions of rTMS on craving for cigarettes and
186 level of consumption of cigarettes in smokers. The first studies were conducted to evaluate the effect of
187 a single rTMS session over the left DLPFC on craving. Johann et al. (2003) found that smokers rated
188 craving for cigarettes lower on a visual analog scale (VAS) after a session of active high frequency
189 rTMS (20 Hz; 90% of resting motor threshold (RMT), compared to sham rTMS (Johann et al., 2003).
190 However, in a double-blind crossover study with 2 active (20 Hz; 90% RMT) and 2 sham sessions,
191 Eichhammer et al. (2003) evaluated craving with a similar VAS and found no differences in craving
192 between sham and active conditions. Nonetheless, they did find that subjects smoked less cigarettes
193 after active rTMS as compared to sham (Eichhammer et al., 2003). Following those two pioneering
194 studies, Amiaz et al. (2009) assessed the effects of rTMS on cue-induced craving and urinary cotinine.
195 In this parallel study, 48 treatment-seeking smokers were individually assigned to one of the following
196 categories; rTMS (10 Hz; 100% RMT) with presentation of smoking cues, rTMS with presentation of
197 neutral cues, sham rTMS with presentation of smoking cues, and sham rTMS with presentation of
198 neutral cues. rTMS sessions were administered during 10 consecutive weekdays. Craving was assessed
199 before, immediately after and 6 months after the end of the rTMS arm. Urinary cotinine levels were
200 measured before stimulation on days 1, 5 and 10. Smokers who received active rTMS (with neutral or
201 smoking cues) reported a decrease in craving and a decrease in cigarette consumption and urinary
202 cotinine levels, but these effects were not significant after the follow-up period of six months (Amiaz et
203 al., 2009). Rose et al. (2011) tested the effect of combining bilateral rTMS with a smoking-cue
204 condition. The smoking-cue condition consisted of presentation of smoking-related pictures and
205 holding a cigarette and a lighter. There was also a neutral cue condition, which consisted of
206 presentation of neutral pictures and holding a pencil and rubber eraser. They delivered low frequency
207 (1 Hz; 90% RMT) and high frequency bilateral rTMS (10 Hz; 90% RMT) over the superior frontal
208 gyrus (SFG). All participants received both types of stimulation and an active control condition with
209 stimulation (1 Hz; 90% RMT) to the motor cortex. High frequency rTMS to the SFG induced craving
210 during the smoking cue condition, whereas low frequency rTMS had no significant effect. In an
211 additional condition, they combined stimulation with controlled inhalation of actual cigarette smoke, by
212 means of a controlled cigarette puff volume apparatus. Prior to stimulation, subjects inhaled a cigarette
213 with the apparatus to determine the volume of smoke normally inhaled with each puff. During
214 stimulation, subjects inhaled this volume of cigarette smoke. In this condition, active high frequency
215 rTMS decreased craving ratings (Rose et al., 2011). Taken together, these results provide interesting
216 insight on the role of the SFG in provoking opposite behavioural impact following stimulation:
217 increasing or suppressing craving. More recently, Li et al. (2013) used a crossover paradigm in which
218 subjects received sham and active rTMS (10Hz, 100% RMT) over the left DLPFC, with a one-week
219 interval separating the two rTMS sessions. Subjects were presented neutral and cigarette-smoking
220 visual cues, before and after stimulation, and completed the Questionnaire of Smoking Urges. Active as
221 compared to sham rTMS reduced craving ratings (Li et al., 2013a). When comparing these results with
222 the ones from Johann (2003) and Eichhammer (2003), the authors propose that these immediate effects
223 may partly be ascribable to the increased number of pulses during the stimulation period (1000 pulses
224 per session for Johann et al. and Eichhammer et al.; 3000 pulses per session for Li et al.). Interestingly,
225 greater reduction in smoking cravings were correlated with greater FTND scores and number of
226 cigarettes smoked per day at baseline. The authors thus suggest that rTMS may be of particular clinical
227 importance in difficult-to-treat smokers. Pripfl et al. (2013) investigated the neural mechanisms

228 underlying nicotine-craving reduction. They used high frequency rTMS (10Hz; 90%MT) applied to the
229 left DLPFC in smokers who were required to remain abstinent for 6 hours before stimulation. They
230 also recorded EEG delta brain waves before and after stimulation, which are presumably associated to
231 activity in the dopamine pathways and thought to be a neurobiological correlate of craving. They found
232 that both craving ratings and EEG delta power were reduced after active stimulation as compared to
233 sham (Pripfl et al., 2013). These results suggest that rTMS may impact the dopamine reward pathways
234 and may be one of its primary mechanisms of action in the reduction of craving. Finally, Dinur-Klein et
235 al. (2014) investigated the preclinical efficacy of 13 sessions of either 10Hz rTMS, 1Hz rTMS or sham
236 stimulation on craving and cigarette smoking (measured with urinary cotinine levels) in 115 treatment-
237 seeking smokers. They have used an H-shape coil, which allowed to target both the lateral PFC and
238 insula (Zangen et al., 2005). Craving levels were measured with the Short Tobacco Craving
239 Questionnaire and visual smoking cues were presented to the subjects before each rTMS sessions. High
240 frequency rTMS significantly reduced both craving and cigarette smoking compared to low frequency
241 rTMS (1 Hz) and sham rTMS, reaching an abstinence rate of 33% at a 6-month follow-up (Dinur-Klein
242 et al., 2014). The authors suggest that stimulation of reward sensitive areas in deeper layers of the
243 cortex, such as the insula, may be more efficient to decrease cravings and achieve abstinence.

244
245 In summary, over a total of eight experiments of rTMS in TUD, five have found a decrease in tobacco-
246 related craving, two have reported no changes, and one observed an increase in craving. In regards to
247 stimulation parameters, all five studies reporting decreases in craving used high frequency rTMS, three
248 targeted the left DLPFC, one targeted the midline SFG and one targeted the lateral PFC. On the two
249 studies reporting no changes, one delivered 1 Hz rTMS and one 20 Hz rTMS. The only study reporting
250 craving increase used low frequency rTMS. In regards to subjects' characteristics, two studies among
251 the five that reported a decrease in craving required subjects to be abstinent before stimulation and two
252 did not require abstinence. One study reporting craving decrease tested treatment-seekers. In terms of
253 experimental paradigm, three of the five studies used a cue-provoked paradigm (see Table 1).

254 255 *Transcranial electric stimulation in tobacco use disorders*

256 tES applied over the DLPFC may also induce changes in craving and cigarette consumption in TUD. A
257 first study by Fregni et al. (2008) sought to determine if tES could modulate cigarette craving in
258 smokers. This study employed a randomized, double-blind, sham-controlled crossover design. Craving
259 were elicited with the presentation of a smoking-related video, and rated before and after the video cue
260 on a VAS. A single session of anodal stimulation of either the right or left DLPFC coupled with
261 cathodal stimulation of the contralateral DLPFC (20min; 2 mA) decreased craving when compared to
262 sham stimulation (Fregni et al., 2008). A subsequent study by Boggio et al. (2009) sought to determine
263 if repeated sessions of anodal stimulation of left DLPFC coupled with cathodal stimulation of the right
264 DLPFC (20min; 2 mA) might induce a longer-lasting decrease in the number of smoked cigarettes and
265 craving. Active stimulation decreased the number of smoked cigarettes compared to sham tES
266 throughout the 5-day intervention. Interestingly, the effect was reported as dose-dependent, as the
267 effect of tES seemed to gain magnitude depending on the number of sessions. Moreover, active tES
268 diminished craving ratings compared to sham tES (Boggio et al., 2009). We recently investigated the
269 effect of tES (30min, 2 mA, anodal over the left DLPFC coupled with cathodal over the right DLPFC)
270 on the number of smoked cigarettes in smokers who wished to quit (Fecteau et al., 2014). Subjects
271 received two five-day regimens of active and sham tES. The number of smoked cigarettes was
272 collected throughout the experiment. We found that active as compared to sham tES reduced the
273 number of smoked cigarettes and the effect lasted up to four days after the end of the stimulation
274 session. Subjects also performed two versions the Ultimatum Game task, the original task with
275 monetary reward and a modified version of the task with cigarettes as reward. The Ultimatum Game
276 assesses cognitive processes involving decision-making. Subjects can either accept or reject an offer

277 made by a proposer. The offer consists of splitting a reward in unequal parts, to the advantage of the
278 subject or not. If the subject accepts the offer, the reward is split as proposed, but if not, no one receives
279 the reward (e.g., Sanfey, 2003). Active tES induced a more conservative approach in the Ultimatum
280 Game as smokers refused more offers of cigarettes. This study thus suggests that tES applied over the
281 DLPFC may modulate reward-sensitive processes. Of interest, Pripfl et al. (2013) have shown that
282 anodal stimulation (with 3 electrodes) of the right DLPFC coupled with cathodal of the left DLPFC
283 (15min; 0.45 mA) improved controllability of impulsivity in smokers. There were no effects with
284 cathodal stimulation of the right DLPFC coupled with anodal tES of the left DLPFC and sham
285 stimulation. Although this work did not investigate craving, it suggests differential effects of tES in
286 smokers and healthy subjects on a cognitive process, impulsivity, known to be impaired in some
287 smokers. Xu et al. (2013) used anodal tES (20min; 2 mA) over the left DLPFC, with the cathode over
288 the right supraorbital area, in smokers to assess changes in craving and negative affects with the Profile
289 of Mood States questionnaire. Active tES reduced tension, anxiety and depression indices, but did not
290 change craving (Xu et al., 2013). Finally, Meng et al. (2014) have studied the effects of a single session
291 of tES on the number of cigarettes smoked on the following day and attention bias to smoking-related
292 cues using an eye-tracking system. There were 3 stimulation conditions (20 min, 1 mA): cathodal
293 stimulation over the frontal-parietal-temporal area (FPT) of both hemispheres with anodal stimulation
294 over both occipital cortices; cathodal stimulation over the right FPT and anodal stimulation over the
295 right occipital cortex; and sham tES. Main findings were a decrease of cigarette consumption in
296 subjects who received bilateral cathodal tES over the FPT and an attentional shift from smoking-related
297 to neutral cues as compared to the other groups (Meng et al., 2014). In summary, these results provide
298 interesting support for the clinical potential of tES in TUD (see Table 1).
299

300 Over a total of four studies assessing the use of tES on tobacco-related craving, all delivering 2 mA,
301 two have reported a decrease in craving, one reported a decrease in craving in one subscale over a total
302 of four, and one study found no changes in craving (see Table 1). The three studies reporting a decrease
303 in craving targeted both DLPFCs whereas the study reporting no changes applied anodal stimulation to
304 the left DLPFC and cathodal over the right supraorbital area. In regards to subjects, three of the studies
305 reporting decreases in craving did not require subjects to be abstinent, whereas subjects were abstinent
306 for a minimum of ten hours in the other study. Only one study recruited treatment-seekers and all four
307 studies used a cue-provoked paradigm.

308
309 Please insert Table 1 about here

310
311

312 **Noninvasive brain stimulation in alcohol use disorder**

313

314 Alcohol is the most widely used psychoactive substance and AUD is a frequent condition worldwide.
315 AUD is a severe condition, preoccupying social issue and a complex phenomenon as various
316 concomitant psychiatric conditions, such as mood disorders, are encountered among alcoholic patients
317 (Vengeliene et al., 2009).

318

319 *Neural substrates of alcohol use disorders*

320 Ethanol is the main psychoactive ingredient in alcohol intake and acts as a CNS depressant. As a
321 nonselective pharmacological agent, ethanol easily penetrates the brain blood barrier and acts primarily
322 by disrupting receptors and ion channels, affecting a broad range of neurotransmitter systems within
323 the human brain. Its poor selectivity makes it difficult to identify which of its effects are ascribable to a
324 particular neural system or receptor interaction. Following heavy consumption and intoxication,
325 alcohol inhibits L-type Ca^{2+} channels and facilitates the opening of G-protein activated K^{+} channels,

326 resulting in the inhibition of NMDA receptors activation. This reduces excitation and allows the
327 enhancement of GABA_A receptor function, increasing inhibition. The resulting concentration of ethanol
328 in blood and affinity of the subunit of the receptor or channel interacting with ethanol are thought to be
329 the main parameters depicting alcohol's psychoactive effect (Vengeliene et al., 2009). Alcohol's action
330 on intrinsic membrane properties can lead to various molecular mechanisms involving
331 neurotransmitters and second messengers, including serotonergic (5-HT₃) receptors present on
332 GABAergic interneurons. Potentiation of 5-HT₃Rs by alcohol consumption enhances the inhibitory
333 action of GABA. Moreover, activation of 5-HT₃ and nAChRs facilitates the release of dopamine and
334 leads to the modulation of glutamate, GABA, acetylcholine and norepinephrine transmissions
335 (Vengeliene et al., 2009). Therefore, the pleasurable and reinforcing properties of ethanol depend on
336 the indirect stimulation of the mesolimbic pathway, mediated by the modulation of glutamatergic
337 systems and disinhibition of dopamine neurons. Additionally, results also suggest that ethanol may
338 directly excite dopamine neurons in the VTA and thus stimulate the release of dopamine (Sulzer,
339 2011). It is also thought that the decrease in K⁺ currents and activation of inward currents by
340 acetaldehyde, a metabolite of ethanol, may be partly responsible for dopamine neurons firing (Sulzer,
341 2011). However, it is important to note that even though dopamine remains a key player in alcohol
342 reinforcement, opiates and cannabinoids are also involved in the initiation and maintenance of AUD. In
343 humans, approved pharmacotherapies for AUD comprise disulfiram (an acetaldehyde dehydrogenase
344 inhibitor), naltrexone (an opioid-receptor antagonist) and acamprosate (acts on normalizing NMDA
345 hyperexcitability during withdrawal)(Lev-Ran et al., 2012). The aforementioned compounds are
346 relatively effective in diminishing alcohol craving but also induce serious side effects.

347 348 349 ***Repetitive transcranial magnetic stimulation in alcohol use disorders***

350 In one of the first rTMS studies in AUD, Mishra et al. (2011) administered ten daily sessions of 10 Hz
351 rTMS (110% RMT) over the right DLPFC to 30 AUD patients and compared the effects to that of
352 sham stimulation in 15 patients. They evaluated craving for alcohol with the Alcohol Craving
353 Questionnaire after each rTMS session. They also evaluated craving one month after the final rTMS
354 session. Patients had to remain sober during ten consecutive days before the rTMS session. Active
355 compared to sham rTMS reduced craving scores after the ten days of stimulation. The authors propose
356 that rTMS over the DLPFC may facilitate the stimulation of dopamine pathways through the meso-
357 fronto-limbic connections. They also suggest a possible transhemispheric suppression of the left
358 DLPFC may have resulted from the stimulation of the right DLPFC. Although these hypotheses remain
359 to be tested in future work, this study highlights the potential efficacy of high-frequency rTMS in
360 diminishing craving intensity in AUD (Mishra et al., 2011). Höppner et al. (2011) have also assessed
361 the effect of high frequency rTMS in 19 female AUD patients, stimulating the left DLPFC in ten
362 consecutive session with 20 Hz rTMS (90% RMT). They assessed craving for alcohol with the
363 Obsessive Compulsive Drinking Scale (OCDS) and depressive symptoms with two different scales
364 (Hamilton Scale and Beck's Inventory). No significant differences were found in craving and mood
365 when comparing active and sham rTMS groups (Höppner et al., 2011). Herremans et al. (2012) focused
366 on the effect of a single session of high frequency rTMS (20Hz; 110% RMT) over the right DLPFC on
367 alcohol craving. The study regrouped 36 AUD patients detoxified for 12 days and evaluated alcohol
368 craving with the OCDS before and after the single rTMS session. The authors report no significant
369 differences in alcohol craving when comparing active to sham rTMS groups. It is worth noting that the
370 rTMS was delivered at home and that these patients had stopped taking medication (benzodiazepine)
371 before the experiment (Herremans et al., 2012). Following this study, the same research group
372 (Herremans et al., 2013) assessed the effect of a single session of rTMS (20Hz; 110% RMT) over the
373 right DLPFC in AUD patients detoxified for 14 days. They measured alcohol craving with the OCDS
374 and found no effect of active or sham rTMS on craving, similarly to their first study. Finally, a single

375 case report from De Ridder et al. (2011) delivered 15 sessions of 1Hz rTMS over the medial frontal
376 cortex to decrease alcohol craving in a severe AUD patient. The patient gained beneficial effects over
377 withdrawal symptoms for three months post-treatment. The patient relapsed after this three-month
378 period and was treated again with five rTMS daily session and relapsed again three weeks post-
379 treatment (De Ridder et al., 2011). Although this case report includes a single subject, it highlights the
380 transient effects obtainable with repeated sessions of rTMS.

381
382 In sum, two studies (Mishra et al. 2011; De Ridder et al. 2011) have shown a significant decrease in
383 alcohol craving following active stimulation and three studies have reported negative findings
384 (Herremans *et al.*, 2012, 2013; Höppner et al., 2011). Diverse stimulation parameters and different types
385 of patients may have caused the important discrepancies between results in the aforementioned studies.
386 In regards to stimulation parameters, one study used 10Hz over the right DLPFC and the other 1 Hz
387 over the dorsal ACC. The three unsuccessful studies all used 20 Hz, one over the left DLPFC and two
388 over the right DLPFC. All studies required their subjects to be abstinent, as most of them were
389 treatment-seeking in-clinic patients. One of the two studies reporting a decrease in craving used a cue-
390 provoked paradigm and the other did not. The three studies reporting no changes in craving did not use
391 a cue-provoked paradigm to assess the effect of rTMS on craving. In regards to craving assessments,
392 one study used the ACQ-NOW with 5 factors and one used a single item VAS. The other studies used
393 the OCDS (see Table 2).

394 395 ***Transcranial electric stimulation in alcohol use disorders***

396 Boggio *et al.*, (2008) have investigated the effect tES on alcohol craving, with 13 abstinent AUD
397 patients who were administered bilateral tES over the right and left DLPFCs. In this cue-elicited
398 paradigm, patients were presented alcohol-related visual cues to induce craving before stimulation.
399 Both active tES electrode montages (anodal to the left with cathodal to the right; cathodal to the left
400 with anodal to the right; both conditions at 2mA for 20 min) reduced craving compared to sham
401 stimulation (Boggio et al., 2008). More recently, Nakamura-Palacios et al. (2012) used 1mA tES during
402 10 min in 7-days abstinent alcoholics to decrease craving (Anodal left DLPFC; cathodal right
403 supradeltoid area) (Nakamura-Palacios et al., 2012). They found no significant changes in craving on
404 the OCDS. da Silva et al. (2013) studied the effect of five weekly tES sessions (anodal stimulation of
405 the left DLPFC coupled with cathodal stimulation of the right supradeltoid area, 2mA for 20min) in a
406 clinical population of alcoholics. They focused on the effects on craving, event-related potentials
407 following presentation of alcohol-related visual cues, and depression and anxiety symptoms. Active
408 tES and sham stimulation decreased craving and depressive symptoms. This decrease in both
409 measurements was larger and more significant in the active tES group. Active compared to sham tES
410 also triggered DLPFC activity during the presentation of alcohol-related cues. There was no significant
411 effect on anxiety symptoms. Furthermore, 2 out of 6 patients in the active group and 6 out of 7 in the
412 sham group remained abstinent during the five-week trial, the others relapsed (da Silva et al., 2013).
413 Finally, den Uyl and colleagues (2015) studied the effect of tDCS over alcohol craving in hazardous
414 drinkers from a student population. They compared two electrode montages; one with the anode over
415 the left DLPFC and the cathode over the right supraorbital area, and one with the anode over the left
416 IFG and the right supraorbital area. They measured craving with the Alcohol Approach and Avoidance
417 Questionnaire (AAAQ) before and after tDCS but did not include a cue-provoked paradigm. Active
418 tDCS with the anode over the left DLPFC reduced craving compared to sham (den Uyl et al., 2015).

419
420 Over a total of four studies, three have reported a decrease in craving, with two studies using 2mA and
421 one 1mA. One study used a bilateral montage with the anode and cathode over both DLPFCs, and two
422 delivered anodal stimulation of the left DLPFC and cathodal over the right supradeltoid area. The
423 fourth study which did not report changes in craving delivered 1 mA tDCS with anodal stimulation of

424 the left DLPFC and cathodal of the right supraorbital area. In regards to the patients, they were all
425 abstinent across the studies, except for the den Uyl study, which included hazardous drinkers among a
426 student population. In regards to craving measurements, between the three successful studies, one used
427 the AUQ, one the OCDS and one the AAAQ. All studies used a cue-provoked paradigm, except for the
428 den Uyl study which only measured baseline craving before and after tDCS. The study from
429 Nakamura-Palacios and colleagues (2012), which reported no changes, used the OCDS to assess
430 alcohol craving but did not use a cue-provoked paradigm (see Table 2).

431

432 Please insert Table 2 about here

433

434

435 **Noninvasive brain stimulation in psychostimulant use disorders**

436

437 Cocaine is a powerful psychostimulant of the CNS and thus directly stimulates the release of dopamine
438 in the mesocorticolimbic pathways. It is a highly addictive substance, with an estimate 1.7 million
439 patients in the US (NIDA, 2012). Cocaine use disorder is strongly characterized by relapse and
440 recidivism (Dackis and O'Brien, 2001; Stahl, 2005). Methamphetamine (METH), a methylated
441 derivative of amphetamines, is similarly addictive and stimulating to the dopamine circuits. Its
442 popularity has reached epidemic proportions throughout the world, with an estimated 25 million users
443 worldwide (Cadet and Krasnova, 2009). Its pharmacological action is of longer duration and chronic
444 intake can result in severe and long-lasting neuropsychiatric adverse effects, due to its neurotoxic
445 effects on the dopamine and serotonin terminals (Marshall and O'Dell, 2012; Völm et al., 2004).

446

447

448 *Neural substrates of psychostimulant use disorders*

449 Cocaine acts as an indirect agonist at dopamine receptors and as an inhibitor of monoamine
450 transporters (such as DAT, the dopamine transporter). Therefore, its double action stimulates the
451 release of dopamine and blocks the reuptake mechanism of dopamine neurons (Stahl, 2005), causing an
452 accumulation of dopamine in the synaptic cleft. This causes dopamine concentration to reach a non-
453 physiological level and drastically enhances dopamine transmission. Behavioral effects on cocaine
454 users are mainly mediated by these mechanisms although cocaine also has effects on
455 norepinephrinergic and serotonergic neurons. METH also stimulates release of dopamine and,
456 partially, serotonin, and additionally transiently reverses monoamine transporters (DAT, SERT) thus
457 increasing extracellular concentration of such transmitters (Völm et al. 2004).

458

459 Repeated and chronic psychostimulants intake eventually facilitates the down-regulation of D2
460 receptors concentration in the prefrontal cortex, leading to an increase in D1 receptors signaling,
461 thought to increase glutamate transmission and facilitate glutamate release in cortico-limbic
462 projections. Eventually, this leads to the augmentation of dendritic spines, insertion of AMPA receptors
463 and the increase in AMPA receptor sensitivity of the postsynaptic density of GABA medium spiny
464 neurons of the NA, which will affect the metabotropic glutamate receptors (mGluRs) (Kalivas, 2007a;
465 Kalivas et al., 2006). In fact, partial inhibition of glutamate release in the DLPFC and partial blockade
466 of mGluRs are pharmacological experimental avenues to suppress cocaine use disorder, as
467 demonstrated in studies in which blocking AMPA receptors on the NA inhibited relapse (Cornish and
468 Kalivas, 2000; Kalivas, 2007b; Kalivas et al., 2005). Targeting GABA transmission is another
469 interesting avenue to regulate psychostimulant craving. GABA levels in the ventral pallidum (VP) have
470 been reported lower than normal in patients with cocaine abuse and decrease in GABA concentrations
471 in this structure has been associated with cocaine-seeking behaviors and development of cocaine
472 sensitization (Kalivas, 2007b). Increase of glutamate release near limbic structures during cocaine

473 administration is thought to modulate GABA transmission and GABA projections from the NA to the
474 VP, among other structures. Interestingly, outputs from the NA to the VP are also peptidergic, and
475 chronic psychostimulant intake can induce long-term changes in opioid peptides regulation, namely on
476 β -endorphin in the NA and dynorphin in striatal neurons. All opioid receptors from the basal ganglia
477 are probably involved in the rewarding effect of cocaine administration, although μ - and δ -opioid
478 receptors are most cited (Trigo et al., 2010).

479
480 As for TUD and AUD, the prefrontal areas are of crucial importance in the development and
481 maintenance of psychostimulants use disorder. For instance, reduced metabolism of the OFC observed
482 in cocaine and METH users is thought to modulate dopamine transmission and facilitate reward
483 sensitivity (Volkow, 2002; Volkow et al., 2011). Studies using NIBS in these populations have thus
484 focused on the DLPFC as a brain target in an effort to decrease craving by modulating activity in the
485 prefrontal region and its connected network.

487 *Repetitive transcranial magnetic stimulation in psychostimulant use disorders*

488 Two studies have sought to test the clinical potential of rTMS in the reduction of cocaine craving. In
489 the first one, Camprodon et al. (2007) have administered two sessions of rTMS (10 Hz, 90 % RMT) in
490 randomized order over the right and left DLPFC of each patient. The six patients were in-clinic and
491 seeking treatment for cocaine use disorder. They completed craving VAS before, after and 4 hours after
492 each of the two rTMS session, which were scheduled at a week interval. Cocaine craving were
493 decreased after rTMS applied to the right, but not the left hemisphere (Camprodon et al., 2007).
494 Although these preliminary results are interesting, the authors suggest that a bigger sample size is
495 needed to confirm the effect and the laterality segregation observed in the main effect. In a second
496 study, Politi et al. (2008) investigated the effect of 10 daily sessions of 15 Hz rTMS over the left
497 DLPFC (100% RMT) in 36 detoxification patients diagnosed with cocaine use disorder. Craving
498 reports and psychosomatic symptoms of abstinence were assessed at each of the ten days (Politi et al.,
499 2008). The results showed a gradual and significant reduction of craving following the course of the
500 rTMS protocol, with the most significant changes occurring at the seventh session according to authors.
501 Finally, Li et al. (2013) have used a single session of 1 Hz rTMS targeting the left DLPFC to decrease
502 METH craving in non-treatment seeking METH users. They found out that active compared to sham
503 rTMS induced craving (Li et al., 2013b). The authors propose that inhibitory action of low frequency
504 rTMS over the prefrontal cortex may allow increased activity of the craving-related subcortical regions.
505 Two of the four experiments described demonstrate that rTMS has potential in the reduction of
506 psychostimulant craving, with several subsequent sessions providing a stronger effect (see Table 3).
507 However, it remains evident that more thorough research has to be conducted, taking into account the
508 type of patient and the optimal stimulation parameters, namely the stimulation target as discussed in
509 (Fecteau et al., 2010).

510
511 The two studies reporting a decrease in craving used high frequency rTMS; one targeted the left
512 DLPFC and the other the right DLPFC. The study reporting no change used high frequency rTMS over
513 the left DLPFC and the study reporting an increase in craving delivered 1Hz rTMS over the left
514 DLPFC. In regards to subjects, they were abstinent in all studies. In regards to outcome measures, the
515 two conditions showing a decrease in craving and the one showing no change did not use a cue-
516 provoked paradigm, whereas the study demonstrating an increase in craving used a cue-provoked
517 paradigm (see Table 3).

518
519 Please insert Table 3 about here

520
521 *Transcranial electric stimulation in psychostimulant use disorders*

522 One study has assessed the effect of tES on cocaine-related cue reactivity (Conti et al., 2014). In this
523 work, they measured event-related potentials cue-reactivity in abstinent crack-cocaine users. They
524 measured craving before and after the first tES session, and after the fifth and final tES sessions. They
525 found that a single session of anodal tES (2 mA, 20min) over the right DLPFC coupled with cathodal
526 tES over the left DLPFC did not decrease craving compared to sham tES (see Table 3). Moreover,
527 there was no effect after 5 sessions of active tES compared to sham. There was no significant effect on
528 cocaine intake at 3-months follow-up, but found that 5 subjects in the active tES group and one for the
529 sham group had remained abstinent (Conti and Nakamura-Palacios, 2014).

530

531 One study has investigated the effect of tES in abstinent male METH-dependent subjects (Shahbabaie
532 et al., 2014). This was a randomized, sham-controlled, double-blind, cross-over design and subjects
533 received one active and one sham stimulation session, with the anode over the right DLPFC and the
534 cathode over the left supraorbital area at 2 mA 20 min with a wash-out period of 72 hours. Craving
535 levels were measured before, during and after each tES session on a 1-item VAS, and were asked to
536 rate their METH craving spontaneously. There was an effect of time (pre, during, post) and stimulation
537 (sham, active) but interaction did not reach significance.

538

539 Over two studies using tES for psychostimulant craving, one demonstrated a decrease in craving and
540 the other did not. They used the same stimulation parameters (20min, 2mA). The one reporting a
541 decrease in craving applied anodal to the right DLPFC and cathodal to the left supraorbital area
542 (Shahbabaie et al., 2014) whereas the one that did not applied anodal stimulation over the right DLPFC
543 and cathodal over the left DLPFC (Conti et al., 2014). In regards to patients, the study reporting a
544 decrease in craving used 1-week abstinent subjects whereas the other study required a minimum of 31-
545 days of abstinence. Both studies used a cue-provoked paradigm (see Table 3).

546

547

548 **General discussion**

549

550 Studies presented in this review provide insight for the use of NIBS in reducing craving and
551 consumption of addictive substances. A recent meta-analysis has explored the effects of rTMS and tES
552 on craving reduction for diverse substances and provided statistical evidence that these techniques can
553 decrease craving levels for food, nicotine, alcohol and marijuana (Jansen et al., 2013). They found an
554 effect size of 0.476, which encourages future investigations. Of interest, there was no significant
555 difference between rTMS and tES in decreasing craving. Moreover, the magnitude of the effects was
556 not different across substances. The authors also tested whether targeting the left or right DLPFC with
557 NIBS induced greater benefits on craving. Although there was no significant statistical difference,
558 greater craving suppression was reported when targeting the right hemisphere.

559

560 Although the results described in this review mainly come from experimental studies, it is worth
561 comparing NIBS with traditional pharmacology and behavioral interventions. SUDs have a high
562 prevalence worldwide, available therapies that are clinically efficient are relatively rare. Most available
563 pharmacotherapies rely either on pharmacological blockade of sensitive receptors or on
564 pharmacological substitution of the substance's active component. In TUD, nicotine replacement
565 therapy and bupropion or varenicline are the most used alternatives for smoking cessation. In AUD,
566 main medications use to limit alcohol withdrawal symptoms include anticonvulsants, antipsychotics
567 and benzodiazepines with limited success (Amato et al., 2011). In psychostimulant use disorder, most
568 common treatments include the use of indirect dopamine agonists that seem to increase
569 psychostimulant abstinence (Pérez-Mañà et al., 2011). In opioid use disorder, methadone maintenance
570 therapy seems an effective replacement therapy that decreases heroin use, but its primary impact is to

571 retain patients in treatment and does not reduce the high mortality rate of patients (Mattick et al., 2009).
572 In sum, current available pharmacotherapies for SUDs are effective for some patients, but still do not
573 meet overall clinical needs (Castells et al., 2010). Behavioral interventions are helpful to achieve
574 clinical success but do not seem to comprise all facets of substance use disorders (Knapp et al., 2008).
575 Overall, meta-analytical researches suggest that, across substances, combination of pharmacological
576 treatment and behavioural intervention may increase clinical success and ameliorate clinical attendance
577 and patient retention (Amato et al., 2011; Knapp et al., 2008; Stead et al., 2012).

578
579 As currently understood, NIBS mechanisms of action in craving would suggest a similarity with
580 pharmacological replacement therapy; if indeed tES and rTMS can provoke dopamine release.
581 Similarly to the conclusions reached in the aforementioned studies, we believe that combination with
582 behavioural intervention would be paramount in the development of successful clinical therapy
583 comprising NIBS. rTMS applied to the DLPFC (George et al., 1996; Pascual-Leone et al., 1996b;
584 O'Reardon et al., 2007) and tES applied over the DLPFC also appears to induce beneficial effects in
585 reducing depressive symptoms. Mechanisms associated with these approaches are still uncovered. It is
586 possible that these NIBS protocols targeting the DLPFC and known to elevate mood, may in turn have
587 a beneficial impact in SUD symptoms, such as decreasing craving and consumption. More studies are
588 needed to assess such potential therapeutic mechanisms of action of rTMS and tES in SUDs. It has also
589 been reported that rTMS (Baeken et al., 2009) and tES (Antal et al., 2014) applied over the DLPFC
590 decreased stress by potentially modulating the HPA axis. Such effects might also contribute to positive
591 effects of NIBS observed in various pathologies including major depression and SUDs. It is well
592 described that stress plays a major role in major depression, through hyper reactivity to stressors, and
593 SUDs, through reinstatement of craving. It has been suggested that some beneficial effects of NIBS in
594 such psychopathologies (major depression and SUDs) may share a common pathway (Brunelin &
595 Fecteau, 2014). There is still however a crucial need for the development of a biophysical model of
596 rTMS and tES to decipher their potentially numerous mechanisms of action of clinical effects.

597 We have discussed several theoretical and technical issues related to the potential use of NIBS in
598 SUDs. It is also worth addressing the potential side effects of such devices. Most common side effects
599 of rTMS are headaches, neck pain and transient hearing changes (Rossi et al., 2009). For tES, side
600 effects reported in the general literature seem similar that the ones reported in studies including patients
601 with SUDs stated in this article. They include headaches, mild tingling, dizziness and increased skin
602 sensibility at the location of electrodes. However, no studies reported disruption of the protocol or
603 resignation of subjects due to side effects. In the context of eventually using NIBS in the treatment of
604 SUDs, it is also important to think of possible side effects. If stimulation of the prefrontal cortex does
605 entail an excitatory effect over cortical and subcortical structures, as suggested by several authors, and
606 promotes the indirect stimulation of the dopamine pathways (Cho & Strafella, 2009), one may propose
607 that NIBS would develop “addictive properties” if administered chronically. Similarly to
608 pharmacological replacement therapy (e.g., nicotine replacement therapy) or cross-sensitization studies
609 (i.e., when a substance is replaced with another substance), NIBS could technically create a shift in
610 SUDs. We propose that this “side effect” would in fact be beneficial as it would, given ideal NIBS
611 parameters and continuous professional counseling, reduce cravings through stimulation of the
612 dopamine pathways, limit the advent of withdrawal symptoms and gradually deplete
613 neuropsychological vulnerability to environmental substance cues and stress associated with substance
614 craving. However, this hypothesis relies on a simplistic explanation of NIBS mechanisms of action;
615 actual mechanisms of action may be far more complex and likely recruit cerebral structures other than
616 the prefrontal cortex and striatum, thus recruiting supplementary neurotransmitter systems other than
617 glutamate and dopamine.

618

619 Although experimental results are promising, the mechanisms of action of NIBS underlying its
620 potential in reducing craving and substance use have yet to be characterized and several questions
621 remain unanswered. Here we delimitate four general categories of factors that can mediate the effects
622 rTMS or tES on craving: 1) stimulation parameters, 2) subjects' brain state, 3), experimental measures
623 of craving and 4) the sample characteristics.

624

625 *1) The effects of stimulation parameters on craving*

626 Stimulation parameters vary across reported studies, and this has to be taken into account for several
627 reasons. First, mechanisms underlying the effects of rTMS and tES remain elusive, even in the healthy
628 resting brain. The possibility for these two techniques of not sharing the same neurophysiological
629 effects cannot be put aside, especially across SUDs. As mentioned in the introduction, rTMS and tES
630 likely have different neurophysiological effects. Specificity of future studies and combination with
631 neuroimaging modalities (e.g., Hone-Blanchet et al., 2015; Bestmann & Feredoes, 2013) will likely
632 help elucidate these differences.

633

634 In addition to this difference between the rTMS and tES devices, the choice of the brain target, the
635 nature of stimulation (presumably known to be excitatory or inhibitory), duration and intensity, all
636 critical aspects in conducting a clinically relevant stimulation protocol, vary highly across studies in
637 SUDs.

638

639 Most studies have targeted the DLPFC with rTMS or tES to diminish craving and substance intake in
640 SUDs. Although a complex network is involved in craving in SUDs, the DLPFC may be one of the
641 only cortical locations targetable by NIBS to impact the dopamine pathways and the insula (Garavan,
642 2010; Kalivas et al., 2005; Naqvi and Bechara, 2009). Indeed, the DLPFC receives direct input from
643 the dopamine mesocortical pathway, originating from the VTA, and projects to the basal ganglia,
644 hippocampus and thalamus (Goldman-Rakic, 1996). It has been reported that rTMS to the DLPFC can
645 enhance dopamine transmission in the striatum (Pogarell et al., 2007), ACC and OFC (Ko and
646 Strafella, 2011); and tES can modulate GABA and glutamate transmission, as shown by the stimulation
647 of the primary motor cortex (Nitsche and Liebetanz, 2004; Stagg et al., 2009). Thus, several authors
648 have proposed that the reduction in craving following stimulation may be mediated by the frontolimbic
649 connections of the DLPFC with structures of the basal ganglia. Moreover, connections from the OFC to
650 the striatum and amygdala, regulating motivational behavior and reward, may also be involved in the
651 observed effect. The DLPFC is also a crucial relay in decision-making processes, and is thought to be
652 essential in the behavioral regulation of craving throughout the prefrontal-striatal pathways (Kober and
653 Mende-Siedlecki, 2010). In brief, among a complex network that has been associated with SUDs, the
654 DLPFC seems to be the best candidate to be non-invasively targeted with NIBS to reduce craving
655 across SUDs. We propose that excitatory stimulation of the DLPFC may act on GABA and glutamate
656 transmission and thus indirectly facilitate dopamine release in the mesocortical pathway, thus
657 transiently reducing substance craving (see Figure 2). The DLPFC has been largely targeted in the
658 studies mentioned in this article. Although this region remains of critical interest, because it is easily
659 targetable from the scalp and relevant in SUDs, other regions may be tested in future work. The insula
660 for instance is becoming a target of primary importance in SUDs. Located inside the lateral sulcus, it
661 receives inputs from the thalamus, parietal, occipital, temporal and frontal cortices. Moreover, it has
662 reciprocal connections with the amygdala and nucleus accumbens. It is activated during drug craving
663 and this activation is correlated with ratings of craving. Pharmacological inactivation or lesions to the
664 insula lead to a disruption of substance craving in animal (Contreras et al., 2007) and humans (Navqi et
665 al., 2007), thus suggesting a paramount role in the maintenance of SUDs. The study by Dinur-Klein
666 and colleagues (2014) used the TMS H-coil, designed to presumably reach subcortical structures such
667 as the insula, with promising results. Similarly, a preliminary study describing TMS administration to

668 decrease chronic pain targeted the right posterior-superior insula in healthy controls, showing changes
669 in cold perception (Ciampi de Andrade et al., 2012). Another target of interest in neuropsychiatric
670 applications of NIBS is the cingulate cortex. Neuroimaging studies have shown that the dorsal part of
671 the ACC is implicated in drug-related cue-reactivity and deficits in inhibitory control among patients
672 with SUDs (Hong et al., 2009; Janes et al., 2013; Yücel et al., 2007). Targeting the ACC, or another
673 region of the prefrontal matrix, could thus act on specific aspects of craving. However, the available
674 biophysical models of TMS and tES strongly suggest that targeting one prefrontal region may very well
675 entail neurophysiological effects on surrounding regions. Of interest, a study from Cho and Strafella
676 (2009) has shown that rTMS of the left DLPFC induces dopamine release in the ipsilateral ACC and
677 orbitofrontal cortex. This advocates for a better understanding of the mechanisms of action TMS and
678 tES to determine what is best: *stimulation of a target for effects over this target* or *stimulation of a*
679 *target for effects over neighboring regions*.

680
681 Please insert Figure 2 about here

682
683 Changes ascribable to neurostimulation are in need of further characterization in humans but animal
684 models will also contribute at deciphering the effects of NIBS that reduce craving. In this regard,
685 Pedron et al. have demonstrated for the first time that anodal tES might be a valid and practical
686 therapeutic alternative in reducing craving. Two daily 20 min sessions of tES for five consecutive days
687 significantly increased working memory and decreased depression-related and addiction-related
688 behaviours (Pedron et al., 2013). Although more results are needed, this consists in important
689 preclinical evidence for the use of NIBS in SUD research. Other animal works have shown that rTMS
690 can enhance dopamine transmission in the mesolimbic pathway (Keck et al., 2002) and tES may
691 increase extracellular dopamine levels in the basal ganglia (Tanaka et al., 2013). It remains important to
692 remember that although SUDs all have the dopamine pathways as a common denominator, several
693 other neurotransmitter systems are involved in this pathology of neuroadaptation.

694
695 Precise localization of the brain target is another critical factor in safe and accurate delivery of brain
696 stimulation. When targeting the DLPFC with rTMS, studies have largely used anatomical information
697 provided by neurological atlases and mapping of Brodman areas, thus localizing the DLPFC as the
698 midpoint of a line drawn from two points taken anteriorly and laterally 5cm from the vertex. Other
699 studies have also located the DLPFC by moving 6cm anteriorly from the primary motor cortex. TMS-
700 compatible neuronavigation methods offer more reliability, as they allow registering a tridimensional
701 brain target with the TMS coil to ensure pulses are given at the same spot (Rusjan et al., 2010; Hone-
702 Blanchet et al., 2015). Moreover, such neuronavigation system can also use previously acquired MR
703 anatomical information of a given SUD patient and thus offer more precision and importantly, take into
704 account inter-individual variability (Fox et al., 2012). Only one rTMS study reported in this review has
705 used neuronavigation (Pripfl et al., 2013), whereas the rest have used manual methods for the
706 localization of the DLPFC or did not report the method of brain targeting. Studies have shown that
707 neuronavigation compared to manual localization of brain targets can increase the effect of brain
708 stimulation and may help provide greater clinical benefits (Bashir et al., 2013). When delivering tES,
709 all reviewed studies have used the 10-20 EEG International System to locate the DLPFC (electrodes
710 positioned over F3 and F4).

711
712 Studies have targeted the DLPFC with low or high frequencies rTMS or anodal and/or cathodal tES to
713 suppress craving. These stimulation parameters are known to induce different direct and distal effects
714 in the brain as shown by neuroimaging studies in the healthy resting brain. These effects have been
715 demonstrated by fMRI, MR spectroscopy and with electrophysiology. For instance, low frequency
716 rTMS over the DLPFC has been shown to enhance BOLD activation in the contralateral and ipsilateral

717 prefrontal regions (Nahas et al., 2001). Of interest, in a comparative study in healthy subjects, Eldaief
718 et al. (2011) have shown that low frequency and high frequency rTMS of the left posterior inferior
719 parietal lobule have differential effect on the default mode network, with increased connectivity in the
720 low frequency condition.

721
722 Different effects are also observed with tES. Anodal tES applied over the prefrontal cortex can reduce
723 blood oxygenation level-dependent (BOLD) signals in the areas under the electrodes and in the relevant
724 network related to the cognitive processes tested (Holland et al., 2011; Meinzer et al., 2012; Saiote et
725 al., 2013). Cathodal tES over M1 has been demonstrated to reduce glutamate release, and anodal tES to
726 reduce GABA concentration in the primary motor cortex region as measured by MR spectroscopy
727 (Stagg et al., 2009).

728
729 Anodal tES over the DLPFC can also increase resting state functional connectivity strength between
730 the area under electrodes and regions involved in the default mode network in healthy subjects (Keeser
731 et al., 2011; Park et al., 2013). This is critical, especially for patients with SUDs as they show impaired
732 regulation of such networks (Ma et al., 2011). As proposed by (Hanlon et al., 2012), one important
733 question remaining is *Should we target the primary site of craving (i.e., pushing down the hot spot) or*
734 *should we target neighboring regions (i.e., pulling the activity away from the hotspot)?* Then, in
735 regards to NIBS, the main question is *Which stimulation parameters should we use, excitatory and/or*
736 *inhibitory, to reduce craving?* This brings us to the importance of brain state to suppress craving with
737 rTMS or tES.

738 739 **2) The importance of brain state to reduce craving with NIBS**

740 Brain state likely varies throughout an experiment; before, during and after stimulation, which is of
741 crucial importance in the issue of diminishing substance craving with NIBS. Craving has been
742 extensively studied using cue-elicited tasks and fMRI. Cue-elicited paradigms have shown changes in
743 BOLD signals in a complex network, including the DLPFC, OFC, striatum, thalamus, VTA and
744 amygdala (Brody, 2006; Goldstein and Volkow, 2002; McBride et al., 2006; Wilson et al., 2004). In
745 regards to activations observed in the DLPFC, it is not clear yet whether the right and/or the left
746 DLPFC are critical to craving. Studies have shown that the DLPFC is differentially activated
747 depending on treatment status and expectancy, abstinence and withdrawal symptoms, and explicit
748 regulation in tobacco and cocaine use disorder. The DLPFC may be thus implicated in differential ways
749 across SUDs (Jasinska et al., 2014).

750
751 Of further importance, not only experimentally-induced craving leads to a differential pattern of brain
752 activity, but even the addicted brain at rest displays differential pattern of brain activity compared to a
753 healthy resting brain. For instance, more severe dependence to nicotine as assessed by the Fagerstrom
754 Test for Nicotine Dependence questionnaire is associated with weaker resting state functional
755 connectivity between the striatum and dorsal anterior cingulate. It is even suggested that the abnormal
756 resting state functional connectivity in cingulate-striatal fibers may serve as an *in vivo* marker for TUD
757 (Hong et al., 2009; Sutherland et al., 2012). Hence, a crucial question is *Should we apply NIBS in a*
758 *craving brain or in a resting brain?* So far, subjects' brain state has not been controlled and varies
759 importantly in the studies using NIBS to reduce craving reviewed here. Some studies (e.g., Fregni *et al.*,
760 2008) have collected craving ratings using a cue-elicited paradigm immediately before tES. In this
761 study, tES was applied in smokers craving for cigarettes, although this "elicited brain state" was not
762 part of the planned design. Other studies have presented SUD-related pictures and neutral pictures
763 during delivery of NIBS (e.g. Rose et al. 2013). These behavioral paradigms, even when presenting
764 solely neutral cues, have also likely induced a specific brain pattern rather than mimicking the resting
765 brain, such as activating regions involved in attentional processing. Other factors can also play a role in

766 brain state in the context of SUD. For instance, level of expectancy (e.g., if the subject can consume
767 right after the experiment or only after a few hours after the experiment) elicited different brain
768 activations and needs to be controlled in future studies (McBride et al., 2006). This brings us to the
769 third factor, which is the outcome assessment, including the impact of brain state during craving
770 assessment.

771

772 **3) Experimental measures of craving**

773 Studies using NIBS to suppress craving have collected craving ratings in different brain states. For
774 instance, some studies asked their subjects to be abstinent for a number of hours before the experiment,
775 other experimentally induced craving by presenting substances-related cues. It can be discussed that
776 abstinence-induced and cue-induced craving may ultimately represent the same neurological
777 phenomena, but works have demonstrated that in smokers, craving can be induced with cues a few
778 minutes after nicotine smoking (Franklin et al., 2007), suggesting that cue-reactivity may work
779 independently from pharmacological stimulation and abstinence state. Additionally, it is often proposed
780 that cue-induced craving paradigms may be a more ecologically valid approach, as recuperating SUDs
781 patients are sensitive to environmental drug-related cues (Ferguson and Shiffman, 2009; Hone-
782 Blanchet et al., 2014).

783

784 Craving assessment design in itself is also important in determining the effect of NIBS in SUDs. The
785 multiple questionnaires used to assess craving in NIBS studies vary in quality, based on the number of
786 items and subscales and the level of standardization. For instance, some studies asked subjects to rate
787 their craving level by asking a single question (e.g., *How much do you desire to smoke?*). This is a
788 methodological choice that allows the measure of craving at the exact moment (if for instance tested
789 multiple times during a 10-min tES session), which would be difficult if using a longer, more detailed
790 questionnaire. However, one question does not fully capture the different aspects of craving, and from a
791 methodological standpoint likely limits the evaluation of the whole construct of craving and statistical
792 power. We, for instance, reported significant changes in craving only for one specific subscale among
793 the four subscales (Desire to smoke, Anticipation of positive outcome, Relief from negative affect, and
794 Intention to smoke) within the standardized Questionnaire of Smoking Urges from Tiffany and Drobes
795 (1991)(Fecteau et al., 2014). It is thus possible that NIBS only modulates some specific aspects of
796 craving. Another methodological aspect that is essential to consider when discussing studies using
797 NIBS to reduce craving is how ratings of craving were reported. Studies have used either VAS or
798 categorical craving scores. As reported by several authors, categorical scores may not capture small
799 changes in craving that VAS may capture.

800

801 Finally, other methodological aspects important for any NIBS studies are also relevant when addressing
802 SUDs. For instance, control of sham condition and blinding levels are critical in an effort to assess the
803 clinical relevance of NIBS in SUDs and several studies have not reported how these were done.

804 Avoidance of carry over effects is also essential in this regard within repeated sessions paradigms, to
805 determine the effect of the tested stimulation design itself. In line with this, in crossover paradigms,
806 craving assessments need to be assessed before each arm to provide a secure baseline for experimental
807 measurements.

808

809 **4) Tested subjects who may benefit from NIBS?**

810 Finally, patients' characteristics are important to consider when assessing the effects of NIBS on
811 craving in SUDs. For example, age and sex can influence craving (Potenza et al., 2012; Robbins et al.,
812 1998) and the effects of NIBS (Freitas et al., 2013; Meinzer et al., 2012).

813

814 Some factors specific to SUDs are also important. Neuroimaging studies reported that patients' level of
815 engagement towards treatment and anticipation of benefits may impact results, supporting the
816 importance of identifying patients as treatment-seeking or not. For instance, fMRI studies reported
817 differential patterns of activity, especially involving the DLPFC, in regards to whether subjects were
818 treatment-seekers or not (Wilson et al., 2004). Hence, this differential pattern of brain activity related to
819 expectancy status is likely to impact the effects of NIBS. The level of dependence is also important, as
820 neuroimaging studies reported differential patterns of activity accordingly (Hong et al., 2009), which is
821 also likely interfering with the effects of NIBS.

822
823 In the reviewed studies, most patients with AUD also had TUD. In some other studies, patients
824 displayed depressive and anxiety symptoms. Co-occurrence of mood disorders and SUDs (Pettinati et
825 al., 2013) is frequent and is of particular importance, as targeting the DLPFC with NIBS is also known
826 to modulate mood in healthy subjects (e.g. Pascual-Leone et al. 1996; George et al. 1996) and reducing
827 depressive symptoms in patients with depression (e.g., O'Reardon et al., 2007) and in SUD patients
828 (Camprodon et al, 2007). We thus cannot rule out whether NIBS alleviate mood in patients with SUD
829 and whether these effects may in turn partially suppress craving. Subjective level of stress may also
830 influence and/or induce craving, and this relationship is well documented (Potenza et al., 2012; Sinha,
831 2011; Sinha et al., 2006).

832
833 In sum, we propose that identifying and inducing the ideal brain state to obtain the greatest craving
834 reduction with NIBS should be a priority in the amelioration of such alternatives. In the same
835 perspective, combination of NIBS with medication for smoking cessation also has to be considered.
836 Although several clinical studies have used such combination in pain (Fregni et al., 2006) and
837 schizophrenia (Brunelin et al., 2012), no results are readily available in SUDs. This poses the
838 challenges of identifying the possible deleterious interference of NIBS with medication, and
839 determining the optimal dosage of neurostimulation concurrently with medication.

840

841 **Figure legends**

842

843 Figure 1: Illustration of the development and reinstatement of craving in SUDs.

844

845 Figure 2: Summary of the four general categories of factors that can mediate the effects rTMS or tES
846 on craving.

847

Accepted Manuscript

847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895

References

- Amato, L., Minozzi, S., Davoli, M., 2011. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. *Cochrane Database Syst Rev* 6, CD008537.
- Amiaz, R., Levy, D., Vainiger, D., Grunhaus, L., Zangen, A., 2009. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. *Addiction* 104, 653–660.
- Antal, A., Fischer, T., Saiote, C., 2014. Transcranial electrical stimulation modifies the neuronal response to psychosocial stress exposure. *Hum Brain Mapp* 35, 3750–3759.
- Anton, R.F., O'Malley, S.S., Ciraulo, D.A., Cisler, R.A., Couper, D., Donovan, D.M., Gastfriend, D.R., Hosking, J.D., Johnson, B.A., LoCastro, J.S., Longabaugh, R., Mattson, M.E., Miller, W.R., Pettinati, H.M., Randall, C.L., Swift, R.M., Weiss, R.D., Williams, L.D., Zweben, A., 2006. Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence. *JAMA* 295, 2003–2017.
- Baker, T.B., Breslau, N., Covey, L., Shiffman, S., 2012. DSM criteria for tobacco use disorder and tobacco withdrawal: a critique and proposed revisions for DSM-5*. *Addiction* 107, 263–275.
- Baeken, C., De Raedt, R., Leyman, L., 2009. The impact of one HF-rTMS session on mood and salivary cortisol in treatment of resistant unipolar melancholic depressed patients. *J Affect Disord* 113, 100–108.
- Bashir, S., Perez, J.M., Horvath, J.C., Pascual-Leone, A., 2013. Differentiation of motor cortical representation of hand muscles by navigated mapping of optimal TMS current directions in healthy subjects. *J Clin Neurophysiol* 30, 390–395.
- Bechara, A., 2005. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive approach. *Nat Neurosci* 8, 1458–1463.
- Benowitz, N.L., 2009. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. *Annu. Rev. Pharmacol. Toxicol.* 49, 57–71.
- Bestmann, S. & Feredoes, E., 2013. Combined neurostimulation and neuroimaging in cognitive neuroscience: past, present and future. *Ann NY Acad Sci* 1296, 11–13.
- Boggio, P., Liguori, P., Sultani, N., Rezende, L., 2009. Cumulative priming effects of cortical stimulation on smoking cue-induced craving. *Neuroscience* 163, 82–86.
- Boggio, P., Sultani, N., Fecteau, S., Merabet, L., 2008. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study. *Drug Alcohol Depend* 92, 55–60.
- Brody, A.L., 2006. Functional brain imaging of tobacco use and dependence. *J Psychiatr Res* 40, 404–418.
- Brunelin, J., Mondino, M., Gassab, L., Haesebaert, F., Gaha, L., Suaud-Chagny, M.-F., Saoud, M., Mechri, A., Poulet, E., 2012. Examining transcranial direct-current Stimulation (tdCS) as a treatment for Hallucinations in Schizophrenia. *Am J Psychiatry* 169, 719–724.
- Brunelin, J. & Fecteau, S., 2015. Can the effects of noninvasive brain stimulation alleviating neuropsychiatric symptoms result from a common beneficial regulation of the hypothalamic-pituitary-adrenal axis? *Brain Stim* 8, 173–176.
- Cadet, J.L., Krasnova, I.N., 2009. Chapter 5 - Molecular Bases of Methamphetamine-Induced Neurodegeneration, 1st ed, *International Review of Neurobiology*. Elsevier Inc.
- Camprodon, J.A., Martínez-Raga, J., Alonso-Alonso, M., Shih, M.-C., Pascual-Leone, A., 2007. One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. *Drug Alcohol Depend* 86, 91–94.
- Castells, X., Casas, M., Pérez-Mañá, C., Roncero, C., Vidal, X., Capellà, D., 2010. Efficacy of psychostimulant drugs for cocaine dependence. *Cochrane Database Syst Rev* 2, CD007380.

- 896 Ciampi de Andrade, D., Galhardoni, R., Pinto, L.F., Lancelotti, R., Rosi Jr, J., Marcolin, M.A., Teixeira,
897 M.J., 2012. Into the Island: A new technique of non-invasive cortical stimulation of the insula. *Clin*
898 *Neurophysiol* 42, 363-368.
- 899 Cho, S.S., Strafella, A.P., 2009. rTMS of the left dorsolateral prefrontal cortex modulated dopamine
900 release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. *Plos One* 4, e6725.
- 901 Conti, C.L., Nakamura-Palacios, E.M., 2014. Bilateral Transcranial Direct Current Stimulation Over
902 Dorsolateral Prefrontal Cortex Changes the Drug-cued Reactivity in the Anterior Cingulate Cortex
903 of Crack-cocaine Addicts. *Brain Stimul* 7, 130–132.
- 904 Cornish, J.L., Kalivas, P.W., 2000. Glutamate transmission in the nucleus accumbens mediates relapse
905 in cocaine addiction. *J Neurosci* 20, 1-5.
- 906 da Silva, M.C., Conti, C.L., Klauss, J., Alves, L.G., do Nascimento Cavalcante, H.M., Fregni, F.,
907 Nitsche, M.A., Nakamura-Palacios, E.M., 2013. Behavioral effect of transcranial Direct Current
908 Stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence. *J.*
909 *Physiol. Paris* 107, 493–502.
- 910 Dackis, C.A., O'Brien, C., 2001. Cocaine dependence: a disease of the brain's reward centers. *J Subst*
911 *Abuse Treat* 111–117.
- 912 De Ridder, D., Vanneste, S., Kovacs, S., Sunaert, S., Dom, G., 2011. Transient alcohol craving
913 suppression by rTMS of dorsal anterior cingulate: An fMRI and LORETA EEG study. *Neurosci*
914 *Lett* 496, 5–10.
- 915 Dinur-Klein, L., Dannon, P., Hadar, A., Rosenberg, O., Roth, Y., Kotler, M., Zangen, A., 2014.
916 Smoking cessation induced by the deep repetitive transcranial magnetic stimulation of the
917 prefrontal and insular cortices: a prospective, randomized controlled trial. *Biol Psychiatry* 76, 742-
918 749.
- 919 Eichhammer, P., Johann, M., Kharraz, A., Binder, H., Pittrow, D., Wodarz, N., Hajak, G., 2003. High-
920 Frequency Repetitive Transcranial Magnetic Stimulation Decreases Cigarette Smoking. *J Clin*
921 *Psych* 64, 951–953.
- 922 Eldaief, M.C., Halko, M.A., Buckner, R.L., Pascual-Leone, A., 2011. Transcranial magnetic
923 stimulation modulates the brain's intrinsic activity in a frequency-dependent manner. *Proc. Natl.*
924 *Acad. Sci. U.S.A.* 108, 21229–21234.
- 925 Fecteau, S., Agosta, S., Hone-Blanchet, A., Fregni, F., Boggio, P., Ciraulo, D., Pascual-Leone, A.,
926 2014. Drug and Alcohol Dependence. *Drug Alcohol Depen* 140, 78–84.
- 927 Fecteau, S., Fregni, F., Boggio, P.S., Camprodon, J.A., Pascual-Leone, A., 2010. Neuromodulation of
928 Decision-Making in the Addictive Brain. *Subst Abuse* 45, 1766–1786.
- 929 Feil, J., Zangen, A., 2010. Brain stimulation in the study and treatment of addiction. *Neurosci Biobehav*
930 *R* 34, 559–574.
- 931 Ferguson, S.G., Shiffman, S., 2009. The relevance and treatment of cue-induced cravings in tobacco
932 dependence. *J Subst Abuse Treat* 36, 235-243.
- 933 Fox, M.D., Buckner, R.L., White, M.P., Greicius, M.D., Pascual-Leone, A., 2012. Efficacy of
934 transcranial magnetic stimulation targets for depression is related to intrinsic functional
935 connectivity with the subgenual cingulate. *Biol Psychiatry* 72, 595–603.
- 936 Franklin, T.R., wang, Z., Wang, J., Sciortino, N., Harper, D., Li, Y., Ehrman, R., Kampman, K.,
937 O'Brien, C.P., Detre, J.A., Childress, A.R., 2007. Limbic Activation to Cigarette Smoking Cues
938 Independent of Nicotine Withdrawal: A Perfusion fMRI Study. *Neuropsychopharmacol* 32, 2301–
939 2309.
- 940 Fregni, F., Boggio, P.S., Lima, M.C., Ferreira, M.J.L., Wagner, T., Rigonatti, S.P., Castro, A.W.,
941 Souza, D.R., Riberto, M., Freedman, S.D., Nitsche, M.A., Pascual-Leone, A., 2006. A sham-
942 controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain
943 in traumatic spinal cord injury. *Pain* 122, 197–209.
- 944 Fregni, F., Liguori, P., Fecteau, S., Nitsche, M., 2008. Cortical stimulation of the prefrontal cortex with

- 945 transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized,
946 sham-controlled study. *J Clin Psych* 69, 32–40.
- 947 Freitas, C., Farzan, F., Pascual-Leone, A., 2013. Assessing brain plasticity across the lifespan with
948 transcranial magnetic stimulation: why, how, and what is the ultimate goal? *Front Neurosci* 7, 42.
- 949 Garavan, H., 2010. Insula and drug cravings. *Brain Struct Funct* 214, 593–601.
- 950 George, M.S., Wassermann, E.M., Kimbrell, T.A., Little, J.T., Williams, W.E., Danielson, A.L.,
951 Greenberg, B.D., Hallett, M., Post, R.M., 1997. Mood Improvement Following Daily Left
952 Prefrontal Repetitive Transcranial Magnetic Stimulation in Patients With Depression: A Placebo-
953 Controlled Crossover Trial. *Am J Psychiatry* 154, 1752–1756.
- 954 George, M.S., Wassermann, E.M., Williams, W.A., Callahan, A., Ketter, T.A., Basser, P., Hallett, M.,
955 Post, R.M., 1995. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in
956 depression. *NeuroReport* 6, 1853–1857.
- 957 Goldman-Rakic, P.S., 1996. The prefrontal landscape: implications of functional. *Philos. Trans. R. Soc.*
958 *Lond., B, Biol. Sci.* 351, 1445–1453.
- 959 Goldstein, R.Z., Volkow, N.D., 2002. Drug Addiction and Its Underlying Neurobiological Basis:
960 Neuroimaging Evidence for the Involvement of the Frontal Cortex. *Am J Psychiatry* 159, 1642–
961 1652.
- 962 Goudriaan, A.E., De Ruiter, M.B., van den Brink, W., Oosterlaan, J., Veltman, D.J., 2010. Brain
963 activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy
964 smokers and healthy controls: an fMRI study. *Addict Biol* 15, 491–503.
- 965 Hanlon, C.A., Jones, E.M., Li, X., Hartwell, K.J., Brady, K.T., George, M.S., 2012. Individual
966 variability in the locus of prefrontal craving for nicotine: implications for brain stimulation studies
967 and treatments. *Drug Alcohol Depen* 125, 239–243.
- 968 Hanlon, C.A., Dowdle, L.T., Austelle, C.W., DeVries, W., Mithoefer, O., Badran, B.W., George, M.S.,
969 2015. what goes up can come down: novel brain stimulation paradigms may attenuate craving and
970 craving-related neural circuitry in substance dependent individuals. *Brain Res.*
- 971 Herremans, S.C., Baeken, C., Vanderbruggen, N., Vanderhasselt, M.A., Zeeuws, D., Santermans, L.,
972 De Raedt, R., 2012. No influence of one right-sided prefrontal HF-rTMS session on alcohol
973 craving in recently detoxified alcohol-dependent patients: Results of a naturalistic study. *Drug*
974 *Alcohol Depen* 120, 209–213.
- 975 Herremans, S.C., Vanderhasselt, M.A., De Raedt, R., Baeken, C., 2013. Reduced Intra-individual
976 Reaction Time Variability During a Go-NoGo Task in Detoxified Alcohol-Dependent Patients
977 After One Right-Sided Dorsolateral Prefrontal HF-rTMS Session. *Alcohol Alcoholism*, 1-6.
- 978 Holland, R., Leff, A.P., Josephs, O., Galea, J.M., Desikan, M., Price, C.J., Rothwell, J.C., Crinion, J.,
979 2011. Speech Facilitation by Left Inferior Frontal Cortex Stimulation. *Curr Biol* 21, 1403–1407.
- 980 Hone-Blanchet, A., Wensing, T., Fecteau, S., 2014. The use of virtual reality in craving assessment and
981 cue-exposure therapy in substance use disorders. *Front Hum Neurosci* 8.
- 982 Hone-Blanchet, A., Salas E.R., Celnik, P., Kallo, A., Schar, M., Puts, N.A.J., Harris, A.D., Barker,
983 P.B., Fecteau, S., Early, C.J., Allen, R.P., Edden, R.A., 2015. Co-registration of magnetic
984 resonance spectroscopy and transcranial magnetic stimulation. *J Neurosci Meth* 242, 52-57.
- 985 Hong, L.E., Gu, H., Yang, Y., Ross, T.J., Salmeron, B.J., Buchholz, B., Thaker, G.V., Stein, E.A.,
986 2009. Association of Nicotine Addiction and Nicotine's Actions With Separate Cingulate Cortex
987 Functional Circuits. *Arch Gen Psych* 66, 431–442.
- 988 Höppner, J., Broese, T., Wendler, L., Berger, C., Thome, J., 2011. Repetitive transcranial magnetic
989 stimulation (rTMS) for treatment of alcohol dependence. *World J Biol Psych* 57–62.
- 990 Hyman, S.E., 2007. Addiction: A Disease of Learning and Memory. *Focus* 5, 220.
- 991 Jansen, J.M., Daams, J.G., Koeter, M.W.J., Veltman, D.J., van den Brink, W., Goudriaan, A.E., 2013.
992 Effects of non-invasive neurostimulation on craving: A meta-analysis. *Neurosci Biobehav R* 37,
993 10, 2472-2480.

- 994 Janes, A.C., Jensen, J.E., Farmer, S.L., Frederick, B., Pizzagalli, D.A., Lukas, S.E., 2013. GABA levels
995 in the dorsal anterior cingulate cortex associated with difficulty ignoring smoking-related cues in
996 tobacco-dependent volunteers. *Neuropsychopharmacol* 38, 1113-1120.
- 997 Jasinska, A.J., Stein, E.A., Kaiser, J., Naumer, M.J., Yalachkov, Y., 2014. Factors modulating neural
998 reactivity to drug cues in addiction: a survey of human neuroimaging studies. *Neurosci Biobehav*
999 *Rev* 38, 1–16.
- 1000 Johann, M., Wiegand, R., Kharraz, A., Bobbe, G., Sommer, G., Hajak, G., Wodarz, N., Eichhammer,
1001 P., 2003. [Repetitiv Transcranial Magnetic Stimulation in Nicotine Dependence]. *Psychiatr Prax*
1002 30, 129–131.
- 1003 Kalivas, P.W., 2007a. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate
1004 neuroplasticity. *Dialogues Clin Neurosci* 9, 389–397.
- 1005 Kalivas, P.W., 2007b. Neurobiology of Cocaine Addiction: Implications for New Pharmacotherapy.
1006 *Am J Addict* 16, 71–78.
- 1007 Kalivas, P.W., O'Brien, C., 2007. Drug Addiction as a Pathology of Staged Neuroplasticity.
1008 *Neuropsychopharmacol* 33, 166–180.
- 1009 Kalivas, P.W., Peters, J., Knackstedt, L., 2006. Animal Models and Brain Circuits in Drug Addiction.
1010 *Molecular Interventions* 6, 339–344.
- 1011 Kalivas, P.W., Volkow, N., Seamans, J., 2005. Unmanageable motivation in addiction: a pathology in
1012 prefrontal-accumbens glutamate transmission. *Neuron* 45, 647–650.
- 1013 Keck, M.E., Welt, T., Müller, M.B., Erhardt, A., Ohl, F., Toschi, N., Holsboer, F., Sillaber, I., 2002.
1014 Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic
1015 and mesostriatal system. *Neuropharmacol* 43, 101–109.
- 1016 Keeser, D., Padberg, F., Reisinger, E., Pogarell, O., Kirsch, V., Palm, U., Karch, S., Moller, H.J.,
1017 nitsche, M.A., Mulert, C., 2011. Prefrontal direct current stimulation modulates resting EEG and
1018 event-related potentials in healthy subjects: A standardized low resolution tomography
1019 (sLORETA) study. *NeuroImage* 55, 644–657.
- 1020 Knapp, W.P., Soares, B., Farrell, M., Silva de Lima, M., 2007. Psychosocial interventions for cocaine
1021 and psychostimulant amphetamines related disorders. *Cochrane Database Syst Rev* 3, CD003023.
- 1022 Ko, J.H., Strafella, A.P., 2011. Dopaminergic Neurotransmission in the Human Brain: New Lessons
1023 from Perturbation and Imaging. *Neuroscientist*.
- 1024 Kober, H., Mende-Siedlecki, P., 2010. Prefrontal–striatal pathway underlies cognitive regulation of
1025 craving. *PNAS* 107, 14811–14816.
- 1026 Koob, G., Volkow, N.D., 2009. Neurocircuitry of addiction. *Neuropsychopharmacol* 35, 217–238.
- 1027 Kuo, M.-F., Paulus, W., Nitsche, M.A., 2013. Therapeutic effects of non-invasive brain stimulation
1028 with direct currents (tDCS) in neuropsychiatric diseases. *NeuroImage* 85, 948-960.
- 1029 Lang, N., Hasan, A., Sueske, E., Paulus, W., Nitsche, M.A., 2007. Cortical Hypoexcitability in Chronic
1030 Smokers? A Transcranial Magnetic Stimulation Study. *Neuropsychopharmacol* 33, 2517–2523.
- 1031 Lev-Ran, S., Balchand, K., Lefebvre, L., Araki, K.F., Le Foll, B., 2012. Pharmacotherapy of alcohol
1032 use disorders and concurrent psychiatric disorders: a review. *Can J Psychiatry* 57, 342–349.
- 1033 Li, X., Malcolm, R.J., Huebner, K., Hanlon, C.A., Taylor, J.J., Brady, K.T., George, M.S., See, R.E.,
1034 2013a. Drug and Alcohol Dependence. *Drug Alcohol Depen* 133, 641–646.
- 1035 Li, X., Malcolm, R.J., Huebner, K., Hanlon, C.A., Taylor, J.J., Brady, K.T., George, M.S., See, R.E.,
1036 2013b. Low frequency repetitive transcranial magnetic stimulation of the left dorsolateral
1037 prefrontal cortex transiently increases cue-induced craving for methamphetamine: A preliminary
1038 study. *Drug Alcohol Depen* 133, 641–646.
- 1039 Ma, N., Liu, Y., Fu, X.-M., Li, N., Wang, C.-X., Zhang, H., Qian, R.-B., Xu, H.-S., Hu, X., Zhang, D.-
1040 R., 2011. Abnormal Brain Default-Mode Network Functional Connectivity in Drug Addicts. *PLoS*
1041 *ONE* 6, 16560.
- 1042 Markou, A., 2008. Neurobiology of nicotine dependence. *Phil Trans R Soc B: Biol Sci* 363, 3159–

- 1043 3168.
- 1044 Marshall, J.F., O'Dell, S.J., 2012. Methamphetamine influences on brain and behavior: unsafe at any
1045 speed? *TINS* 35, 536–545.
- 1046 Mattick, R.P., Breen, C., Kimber, J., Davoli, M., 2009. Methadone maintenance therapy versus no
1047 opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 3, CD002209.
- 1048 McBride, D., Barrett, S.P., Kelly, J.T., Aw, A., Dagher, A., 2006. Effects of Expectancy and
1049 Abstinence on the Neural Response to Smoking Cues in Cigarette Smokers: an fMRI Study.
1050 *Neuropsychopharmacol* 31, 2728–2738.
- 1051 Meinzer, M., Antonenko, D., Lindenberg, R., Hetzer, S., Ulm, L., Avirame, K., Flaisch, T., Floel, A.,
1052 2012. Electrical Brain Stimulation Improves Cognitive Performance by Modulating Functional
1053 Connectivity and Task-Specific Activation. *J Neurosci* 32, 1859–1866.
- 1054 Meng, Z., Liu, C., Yu, C., Ma, Y., 2014. *Journal of Psychiatric Research. J Psychiatr Res* 1–7.
- 1055 Mishra, B.R., Nizamie, S.H., Das, B., Praharaj, S.K., 2011. Efficacy of repetitive transcranial magnetic
1056 stimulation in alcohol dependence: a sham-controlled study. *Addict* 105, 49–55.
- 1057 Nahas, Z., Lomarev, M., Roberts, D.R., Shastri, A., Lorberbaum, J.P., Teneback, C., McConnell, K.,
1058 Vincent, D.J., Li, X., George, M.S., Bohning, D.E., 2001. Unilateral left prefrontal transcranial
1059 magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by
1060 interleaved BOLD fMRI. *Biol Psychiatry* 50, 712–720.
- 1061 Nakamura-Palacios, E.M., de Almeida Benevides, M.C., da Penha Zago-Gomes, M., de Oliveira,
1062 R.W.D., de Vasconcellos, V.F., de Castro, L.N.P., da Silva, M.C., Ramos, P.A., Fregni, F., 2012.
1063 Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current
1064 stimulation in alcoholics according to Lesch alcoholism typology. *Int. J. Neuropsychopharmacol.*
1065 15, 601–616.
- 1066 Naqvi, N.H., Bechara, A., 2009. The hidden island of addiction: the insula. *TINS* 32, 56–67.
- 1067 Nitsche, M., Liebetanz, D., 2004. GABAergic modulation of DC stimulation-induced motor cortex
1068 excitability shifts in humans. *Eur J Neurosci* 19, 2720–2726.
- 1069 Nitsche, M., Nitsche, M., Klein, C., Tergau, F., Rothwell, J.C., Paulus, W., 2003. Level of action of
1070 cathodal DC polarisation induced inhibition of the human motor cortex. *Clin Neurophysiol* 114,
1071 600–604.
- 1072 O'Reardon, J.P., Solvason, H.B., Janicak, P.G., Sampson, S., Isenberg, K.E., Nahas, Z., McDonald,
1073 W.M., Avery, D., Fitzgerald, P.B., Loo, C., Demitrack, M.A., George, M.S., Sackeim, H.A., 2007.
1074 Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major
1075 Depression: A Multisite Randomized Controlled Trial. *Biol Psychiatry* 62, 1208–1216.
- 1076 Park, C.-H., Chang, W.H., Park, J.-Y., Shin, Y.-I., Kim, S.T., Kim, Y.-H., 2013. *Neurosci Lett* 539, 7–
1077 10.
- 1078 Pascual-Leone, A., Rubio, B., Pallardò, F., Català, M.D., 1996. Rapid-rate transcranial magnetic
1079 stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. *The Lancet* 348, 233–
1080 238.
- 1081 Paulus, M.P., Tapert, S.F., Schuckit, M.A., 2005. Neural Activation Patterns of Methamphetamine-
1082 Dependent Subjects During Decision Making Predict Relapse. *Arch gen psych* 62, 761–768.
- 1083 Pedron, S., Monnin, J., Haffen, E., Sechter, D., Van Waes, V., 2014. Repeated Transcranial Direct
1084 Current Stimulation Prevents Abnormal Behaviors Associated with Abstinence from Chronic
1085 Nicotine Consumption. *Neuropsychopharmacol* 39, 981–988.
- 1086 Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M., Capellà, D., 2011. Efficacy of indirect dopamine
1087 agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized
1088 controlled trials. *J Subs Abuse Treatment* 40, 109–122.
- 1089 Perkins, K.A., 2012. Subjective Reactivity to Smoking Cues as a Predictor of Quitting Success.
1090 *Nicotine Tob Res* 14, 383–387.
- 1091 Pettinati, H.M., O'Brien, C.P., Dundon, W.D., 2013. Current status of co-occurring mood and

- 1092 substance use disorders: a new therapeutic target. *Am J Psychiatry* 170, 23–30.
- 1093 Pogarell, O., Koch, W., Pöpperl, G., Tatsch, K., Jakob, F., Mulert, C., Grossheinrich, N., Rupprecht,
1094 R., Möller, H.-J., Hegerl, U., Padberg, F., 2007. Acute prefrontal rTMS increases striatal dopamine
1095 to a similar degree as d-amphetamine. *Psychiatr Res-Neuroim* 156, 251–255.
- 1096 Politi, E., Fauci, E., Santoro, A., Smeraldi, E., 2008. Daily Sessions of Transcranial Magnetic
1097 Stimulation to the Left Prefrontal Cortex Gradually Reduce Cocaine Craving. *Am J Addict* 17,
1098 345–346.
- 1099 Potenza, M.N., Hong, K.-I.A., Lacadie, C.M., Fulbright, R.K., Tuit, K.L., Sinha, R., 2012. Neural
1100 Correlates of Stress-Induced and Cue-Induced Drug Craving: Influences of Sex and Cocaine
1101 Dependence. *Am J Psychiatry* 169.
- 1102 Pripfl, J., Neumann, R., Köhler, U., Lamm, C., 2013. Effects of transcranial direct current stimulation
1103 on risky decision making are mediated by ‘hot’ and ‘cold’ decisions, personality, and hemisphere.
1104 *Eur J Neurosci* 38, 3778–3785.
- 1105 Robbins, S.J., Ehrman, R.N., Childress, A.R., O'Brien, C.P., 1998. Comparing levels of cocaine cue
1106 reactivity in male and female outpatients. *Drug Alcohol Depen* 53, 223–230.
- 1107 Rose, J.E., McClernon, F.J., Froeliger, B., Behm, F.M., Preud'homme, X., Krystal, A.D., 2011.
1108 Repetitive Transcranial Magnetic Stimulation of the Superior Frontal Gyrus Modulates Craving for
1109 Cigarettes. *Biol Psychiatry* 70, 794–799.
- 1110 Rusjan, P.M., Barr, M.S., Farzan, F., Arenovich, T., Maller, J.J., Fitzgerald, P.B., Daskalakis, Z.J.,
1111 2010. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral
1112 prefrontal cortex using novel magnetic resonance image-guided neuronavigation. *Hum Brain Mapp*
1113 31, 1643–1652.
- 1114 Saiote, C., Turi, Z., Paulus, W., Antal, A., 2013. Combining functional magnetic resonance imaging
1115 with transcranial electrical stimulation. *Fr Human Neurosci* 7, 1–7.
- 1116 Sanfey, A.G., 2003. The Neural Basis of Economic Decision-Making in the Ultimatum Game. *Science*
1117 300, 1755–1758.
- 1118 Schwartz, R.S., Benowitz, N.L., 2010. Nicotine Addiction. *N. Engl. J. Med.* 362, 2295–2303.
- 1119 Shahbabaie, A., Golesorkhi, M., Zamanian, B., Ebrahimipoor, M., Keshvari, F., Nejati, V., Fregni, F.,
1120 Ekhtiari, H., 2014. State dependent effect of transcranial direct current stimulation (tDCS) on
1121 methamphetamine craving. *Int. J. Neuropsychopharmacol.* 1–8.
- 1122 Sinha, R., 2011. Effects of Adrenal Sensitivity, Stress- and Cue-Induced Craving, and Anxiety on
1123 Subsequent Alcohol Relapse and Treatment Outcomes. *Arch gen psych* 68, 942.
- 1124 Sinha, R., Garcia, M., Paliwal, P., Kreek, M.J., Rounsaville, B.J., 2006. Stress-Induced Cocaine
1125 Craving and Hypothalamic-Pituitary-Adrenal Responses Are Predictive of Cocaine Relapse
1126 Outcomes. *Arch gen psych* 63, 324–331.
- 1127 Stagg, C.J., Best, J.G., Stephenson, M.C., O'Shea, J., Wylezinska, M., Kincses, Z.T., Morris, P.G.,
1128 Matthews, P.M., Johansen-Berg, H., 2009. Polarity-Sensitive Modulation of Cortical
1129 Neurotransmitters by Transcranial Stimulation. *J Neurosci* 29, 5202–5206.
- 1130 Stahl, S.M., 2005. *Essential Psychopharmacology*, Second Edition. ed. Cambridge University Press.
- 1131 Stead, L.F., Lancaster, T., 2012. Combined pharmacotherapy and behavioural interventions for
1132 smoking cessation. *Cochrane Database Syst Rev* 10, CD008286.
- 1133 Sulzer, D., 2011. How addictive drugs disrupt presynaptic dopamine neurotransmission. *Neuron* 69,
1134 628–649.
- 1135 Sutherland, M.T., McHugh, M.J., Pariyadath, V., Stein, E.A., 2012. Resting state functional
1136 connectivity in addiction: Lessons learned and a road ahead. *NeuroImage* 62, 2281–2295.
- 1137 Tanaka, T., Takano, Y., Tanaka, S., Hironaka, N., Kobayashi, K., Hanakawa, T., Watanabe, K., Honda,
1138 M., 2013. Transcranial direct-current stimulation increases extracellular dopamine levels in the rat
1139 striatum. *Front Syst Neurosci* 7, 1–8.
- 1140 Trigo, J.M., Martín-García, E., Berrendero, F., Robledo, P., Maldonado, R., 2010. The endogenous

- 1141 opioid system: a common substrate in drug addiction. *Drug and alcohol dependence* 108, 183–194.
1142 Vengeliene, V., Bilbao, A., Molander, A., Spanagel, R., 2009. Neuropharmacology of alcohol
1143 addiction. *Br J Pharmacol* 154, 299–315.
- 1144 Volkow, N., 2002. Role of Dopamine, the Frontal Cortex and Memory Circuits in Drug Addiction:
1145 Insight from Imaging Studies. *Neurobiol Learn Mem* 78, 610–624.
- 1146 Volkow, N.D., Wang, G.-J., Fowler, J.S., Tomasi, D., Telang, F., 2011. Addiction: beyond dopamine
1147 reward circuitry. *PNAS* 108, 15037–15042.
- 1148 Völlm, B.A., de Araujo, I.E., Cowen, P.J., Rolls, E.T., Kringelbach, M.L., Smith, K.A., Jezzard, P.,
1149 Heal, R.J., Matthews, P.M., 2004. Methamphetamine Activates Reward Circuitry in Drug Naïve
1150 Human Subjects. *Neuropsychopharmacol* 29, 1715–1722.
- 1151 Wagner, T., Gangitano, M., Romero, R., Théoret, H., Kobayashi, M., Ansel, D., Ives, J., Cuffin, N.,
1152 Schomer, D., Pascual-Leone, A., 2004. Intracranial measurement of current densities induced by
1153 transcranial magnetic stimulation in the human brain. *Neurosci Lett* 354, 91–94.
- 1154 Wassermann, E., Lisanby, S.H., 2001. Therapeutic application of repetitive transcranial magnetic
1155 stimulation: a review. *Clin Neurophysiol* 112, 1367–1377.
- 1156 Wilson, S.J., Sayette, M.A., Fiez, J.A., 2004. Prefrontal responses to drug cues: a neurocognitive
1157 analysis. *Nat Neurosci* 7, 211–214.
- 1158 Wing, V.C., Barr, M.S., Wass, C.E., Lipsman, N., Lozano, A.M., Daskalakis, Z.J., George, T.P., 2012.
1159 Brain stimulation methods to treat tobacco addiction. *Brain Stimul* 6, 221-230.
- 1160 Xu, J., Fregni, F., Brody, A.L., Rahman, A.S., 2013. Transcranial direct current stimulation reduces
1161 negative affect but not cigarette craving in overnight abstinent smokers. *Front Psychiatry* 4, 112.
- 1162 Yücel, M., Lubman, D.I., Harrison, B.J., Fornito, A., Allen, N.B., Wellard, R.M., Roffel, K., Clarke,
1163 K., Forman, S.D., Pantelis, C., 2007. A combined spectroscopic and functional MRI investigation
1164 of the dorsal anterior cingulate region in opiate addiction. *Mol Psychiatry* 12, 691-702.
- 1165
1166

Author, year	Subjects (N)	Design	Stimulus parameters	Targeted regions	Abstinence measures	Craving measures	Main results
Johann et al., 2005, 2011	Smokers (11)	Single-blind, Sham-controlled, Parallel	rTMS 1 session 20 Hz 90% RMT 1000 pulses	L DLPFC	12-hr abstinent, in-clinic	"Desire for smoke" factors scored on VAS	Craving: decreased (active vs. sham)
Eichhammer et al., 2003, 2011	Smokers (14)	Double-blind, Sham-controlled, Parallel	rTMS 2 sessions 20 Hz 90% RMT 1000 pulses	L DLPFC	12-hr abstinent, in-clinic	"Desire for smoke" OCDS scored on VAS	Craving: no change (active vs. sham)
De Ridder et al., 2012	Detoxified Alcoholics (48)	Case report	rTMS 15 sessions 1 Hz 100% RMT 1560 pulses	Dorsal ACC	Abstinent, in-clinic	Urinary cotinine level Subjective self-report of cigarette intake	Cue-provoked craving: Reduced for three months after termination of stimulation protocol (3 weeks). Intake: Reduced during the stimulation protocol
Mohiz et al., 2009	Treatment-seeking smokers (48)	Double-blind, Sham-controlled, Parallel	rTMS 10 sessions 10 Hz 100% RMT 1560 pulses	L DLPFC	No abstinent, in-clinic	Stages of change with a VAS at baseline and follow-up	Cue-provoked craving: decreased in withdrawal symptoms: reduced after the intervention, but not at the 6-month follow-up
Herremans et al., 2012	Detoxified alcoholics (36)	Single-blind, Sham-controlled, Parallel	rTMS 20 Hz 110% RMT 1560 pulses	R DLPFC	Abstinent, in-clinic	Craving: No changes (of smoked sham cigarette in neutral and smoking cue conditions (active vs. sham) after the intervention, but not at the 6-month follow-up. Decreased concentration of urinary cotinine in real stimulation groups (measured at follow-up). Craving: No changes (active vs. sham)	Table 1: Summary of studies assessing craving with TMS and tES in TUD.
Herremans et al., 2013	Detoxified alcoholics (29)	Single-blind, Sham-controlled, Parallel	rTMS 20 Hz 110% RMT 1560 pulses	R DLPFC	Abstinent, in-clinic	Craving: No changes (active vs. sham)	1192
Rose et al., 2011	Smokers (15)	Crossover Double-blind, Sham-controlled, Parallel	rTMS 1 session 1 Hz 90% RMT 450 pulses 2 mA 10 min 90% RMT 4500 pulses	SFG Anodal L DLPFC coupled with cathodal R DLPFC; Anodal SFG R DLPFC coupled with cathodal L	No abstinent	Shiffman-Jarvik Questionnaire before and after neutral cue and cigarette manipulation	Cue-provoked craving: increased with presentation of smoking cues (10Hz vs. 1Hz over SFG). Decreased with presentation of neutral cues (10Hz vs. 1Hz over SFG; 1Hz over SFG vs. 1Hz over SFG) (both configurations) vs. sham).
Boggi et al., 2008	Detoxified alcoholics (13)	Crossover Double-blind, Sham-controlled, Parallel	rTMS 1 session 10 Hz 90% RMT 4500 pulses	SFG R DLPFC coupled with cathodal L	No abstinent	Shiffman-Jarvik Questionnaire before and after neutral cue and cigarette manipulation	Cue-provoked craving: Reduced (both configurations) vs. sham).
Li et al., 2013	Non-treatment seeking Alcoholics (49)	Double-blind, Sham-controlled, Parallel	rTMS 2 sessions 10 Hz 100% RMT 3000 pulses	L DLPFC Anodal L DLPFC, Cathodal R supradeltoid area	2-hr abstinent, in-clinic	Questionnaire of Smoking Urges before and after neutral cues paradigm	Cue-provoked paradigm: active compared to sham rTMS reduced cravings.
Pripfl et al., 2013	Smokers (14)	Single-blind, Sham-controlled, Parallel	rTMS 1 session 10 Hz 90% RMT 1200 pulses 2 mA 20 min	L DLPFC Neuronavigated Anodal L DLPFC coupled with cathodal R supraorbital area	6-hr abstinent, in-clinic	Craving rating on the OCDS "How often do you think you will smoke?" before and after smoking cues	Cue-provoked craving: cravings were reduced (active vs sham).
Silva et al., 2013	Lesch's type IV alcoholics (13)	Single-blind, Sham-controlled, Parallel	rTMS 10 sessions 10 Hz 90% RMT 1200 pulses 2 mA 20 min	Anodal L DLPFC coupled with supraorbital area	Abstinent patients	"How often do you think you will smoke?" before and after smoking cues	Cue-provoked craving: active and sham tDCS decreased cravings
Hayasaka et al., 2013	Smokers (10)	Double-blind, Sham-controlled, Parallel	rTMS 4 sessions 1 Hz 1 mA 10 min	L DLPFC coupled with supraorbital area; Anodal L IFG coupled with cathodal R supraorbital area	4-hr abstinent or no abstinent	"I want to quit now" scored on a VAS	Craving: no change. Craving: Reduced after active tDCS with anode over L DLPFC and cathode over R supraorbital area
Dinur-Klein et al., 2014	Smokers (115)	Double-blind, Sham-controlled, Parallel	rTMS 13 sessions High frequency Low-frequency	Lateral PFC/insula Lateral PFC/insula	No abstinent	Standard craving questionnaire before and after smoking cues Urinary cotinine	Craving: reduction in HF groups vs sham and LF; greater reduction in group presented with smoking cues (HF vs. LF). Intake: reduction of cigarette consumption (urinary cotinine) in HF groups vs sham and LF.

* 1 "I have a desire for a cigarette right now", 2 "If it were possible, I would smoke now", 3 "All I want right now is a cigarette", 4 "I have an urge for a cigarette, 5 "I crave a cigarette right now"

Table 1: Summary of studies assessing craving with TMS and tES in TUD.

Table 2: Summary of studies assessing craving with TMS and tES in AUD.

Author, year	Subjects (N)	Experimental Design	NIBS parameters	Targeted regions	Abstinence Level	Craving measures	Main results
Campridon et al., 2007	Detoxified cocaine users (6)	Crossover	rTMS 1 session 10 Hz 90% RMTT 2000 pulses	L DLPFC R DLPFC	Abstinent	15 items VAS	<u>Craving:</u> Reduced cocaine craving when comparing ratings before and after rTMS to the R DLPFC. No effect on cocaine cravings when comparing ratings before and after rTMS to the L DLPFC.
Politi et al., 2008	Detoxified cocaine users (36)	-	rTMS 10 sessions 15Hz 100% RMT 600 pulses	L DLPFC	Abstinent	Clinical evaluation of psychopathologic symptoms of craving	<u>Craving:</u> Reduced cocaine craving gradually along the course of stimulation protocol.
Li et al., 2013	Non-treatment seeking METH-dependent users (10)	Single-blind, Sham-controlled, Crossover, Control group	rTMS 1 session 15 min 1 Hz 100% MT 900 pulses	L DLPFC	Abstinent	1-item VAS with 0 being "not craving at all" and 10 being "the most craving I've ever had", Before and after drug cues	<u>Cue-provoked craving:</u> active to sham rTMS compared induced cravings in METH-users.
Shahbabaie et al., 2014	METH-dependent patients (30)	Double-blind, Sham-controlled, Crossover	tES 2 mA 20 min	Anodal R DLPFC coupled with cathodal L supraorbital area	1-week abstinent	1-item VAS on subjective craving	<u>Cue-provoked craving:</u> active decreased cravings at rest but increased cravings when administered during exposure to drug cues.
Conti et al., 2014	Crack-cocaine users (13)	Single-blind, Sham-controlled, Parallel	tES 5 sessions 20 min 2 mA	Anodal R DLPFC coupled with cathodal L DLPFC	Abstinent (minimum of 31days)	Brief Cocaine Craving Questionnaire 7 items Before and after drug cues	<u>Cue-provoked craving:</u> no change

Table 3 : Summary of studies assessing craving with TMS and tES in psychostimulant use disorder.